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Michele Nakamura Moore 
 
A RETROSPECTIVE DESCRIPTIVE STUDY OF PAIN SCORES IN 
PRE-DIABETIC PATIENTS ON METFORMIN 
 
Objectives: The purpose was to evaluate pain scores (SF-36 BPS) among pre- 
diabetic patients on metformin or placebo to determine if patients on metformin therapy 
report less pain (higher SF-36 BPS) than patients on placebo. 
Study design: A descriptive retrospective review of pain scores was conducted 
using secondary data analyses of the Diabetes Prevention Program (DPP) and Diabetes 
Prevention Program Outcomes Study (DPPOS) conducted from 1996 to 2008.  Patients 
were randomly assigned to placebo, low (850 mg/day) or high dose (1700 mg/day) 
metformin groups. Pain scores using the SF-36 BPS standard version were taken before 
randomization and annually (year one through four). 
Results:  Out of 3,819 patients that participated in the original study, 1,056 
patients met the current study criteria.  The metformin group included 506 patients and 
the placebo group included 550 patients.  With an alpha level of 0.05 for all analyses, 
baseline pain scores between the metformin group and placebo group showed no 
significant difference.  Year two showed significance between placebo and metformin 
pain scores (75.2 vs 78.6). All other years were not significant.   Comparing low and 
high dose metformin and placebo groups, years one, two and three displayed significant 
differences in pain scores.  In years one and two, the high dose metformin group reported 
less pain than the placebo group (80.7 vs 77.7; 80.1 vs 75.2) and the low dose metformin 
group (80.7 vs 71.8; 80.1 vs 68.6).  In year three, the high dose metformin group had less 
pain than the low dose metformin group (78.4 vs 70.5). 
Conclusion: A high metformin dose is associated with lower reported pain in pre-
vi  
diabetic patients. This study plays an important part in further advancing the exploration 
of metformin’s potential for relieving chronic pain. 
 
 
 
Christina Mushi-Brunt, PhD, MPH, Chair 
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CHAPTER 1: THE PROBLEM 
 
 
1.1 Introduction 
Diabetes affects over 29.1 million of the United States population according to the 
National Diabetes Statistics Report (Centers for Disease Control and Prevention [CDC], 
2014). There are two main types of diabetes, type 1 and type 2. Type 1, also called 
insulin-dependent diabetes mellitus, is a result of insufficient insulin being secreted and 
only accounts for 5% of all diabetes cases.  The more common type of diabetes is type 2 
in which insulin is produced, but cells do not respond to the insulin.  By 2050, diabetes is 
projected to affect 33% of the population (Boyle, Thompson, Gregg, Barker, & 
Williamson, 2010).  The estimated cost of diabetes worldwide in 2014 reached $612 
billion with estimated costs of $10,900 per person in the United States according to the 
International Diabetes Federation (IDF Diabetes Atlas 6
th 
Edition Revision, 2014). 
Pre-diabetes, a precursor to type 2 diabetes, has been estimated to affect 86 
million Americans as of 2012 according to the National Diabetes Statistics Report (CDC, 
2014).  Pre-diabetes is defined by impaired glucose tolerance (IGT) and/or impaired 
fasting glucose (IFG) according to the Standards of Medical Care in Diabetes (American 
Diabetes Association [ADA], 2014).  A diagnosis of pre-diabetes is made when IGT or 
IFG is elevated but not enough to be diagnosed as diabetes (Table 1.1). 
Both type 2 diabetes and pre-diabetes have been linked to obesity, family history 
and inactivity among other factors. Diabetic patients also have a higher risk of high blood 
pressure, high cholesterol, heart disease, stroke, blindness, kidney disease, amputation 
and early death (Harris, 1995).  Among the complications associated with diabetes and 
pre-diabetes is chronic pain (Papanas, Vinik, & Ziegler, 2011). Most often it is diagnosed 
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as painful diabetic neuropathy but can be nociceptive in nature (Lieberman, Peled, & 
Shvartzman, 2014).  The underlying mechanisms behind both nociceptive and 
neuropathic pain are very similar (Chakravarty & Sen, 2010). There are many studies 
regarding neuropathic pain in diabetic patients however, the data regarding nociceptive 
pain and diabetes is scarce.  Therefore, since the underlying mechanisms are similar, 
diabetic neuropathy will be the primary pain condition discussed regarding chronic pain 
in this population. 
 
 
Table 1.1  Range of Blood Glucose Levels For Diagnosis of Pre-diabetes or Diabetes 
 
Diagnoses Impaired Glucose Tolerance Impaired Fasting 
Glucose 
 
Pre-diabetes 
 
140 mg/dl to 199 mg/dl 
 
100 mg/dl to 125 mg/dl 
 
Type 2 Diabetes 
 
200 mg/dl and over 
 
126 mg/dl and over 
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1.2 Diabetic Neuropathy 
 
Painful diabetic neuropathy is initiated by constant high blood glucose levels. 
 
This impairs the blood supply to the nerves as well as causes damage to the myelin sheath 
of axons.  The focus of my work is on peripheral neuropathy that is closely associated 
with pain in the extremities.  Diabetic autonomic neuropathy affecting vascular tone and 
regulation of heart rate will not be examined in this work. 
Painful diabetic neuropathy is thought to be a result of abnormal pain processing 
caused by the damage to the neurons (mainly peripheral but also can be central) 
(Dworkin et al., 2003).  This neuronal damage results in abnormal pain processing which 
is referred to as central sensitization. This abnormal pain processing results in 
unprompted pain, pain from non-painful stimuli and heightened pain. 
 
 
1.3 Epidemiology and Consequences of Diabetic Neuropathy 
 
In 2007, approximately 18,800 patients with diabetes were hospitalized as a result 
of diabetic neuropathy according to the Age-Adjusted Hospital Discharge Rates for 
Peripheral Arterial Disease (PAD), Ulcer/Inflammation/Infection (ULCER), or 
Neuropathy as First-Listed Diagnosis per 1,000 Diabetic Population, United States, 
1988–2007 (Center for Disease Control and Prevention [CDC], 2012). Based on various 
self-report studies, the estimated percentage of patients diagnosed with pre-diabetes that 
have neuropathic pain (13 – 21%) is similar to the percentage of diabetic patients 
diagnosed with painful peripheral neuropathy (8 – 26%) (Papanas et al., 2011). Various 
studies in the United States and other countries have shown that this patient population 
exhibits high pain levels, poor quality of life and inadequate pain management 
(Bouhassira, Letanoux, & Hartemann, 2013 ; DiBonaventura, Cappelleri, & Joshi, 
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2011; Jacovides et al., 2014; Sadosky et al., 2013; Taylor-Stokes, Pike, Sadosky, 
Chandran, & Toelle, 2011). 
 
 
1.4 Treating Diabetic Neuropathy 
 
To address the pain associated with diabetic neuropathy, the Food and Drug 
Administration (FDA) has approved three medications.  These medications are 
pregabalin (Lyrica), duloxetine (Cymbalta) and tapentadol HCl (Nucynta ER). These 
medications have shown mixed results and may have questionable efficacy and 
tolerability (Dworkin et al., 2010).  All of these medications have one mechanistic 
commonality in that they all target the neuronal synapse. 
One novel pain pathway that has not thoroughly been explored in painful diabetic 
neuropathy is the mTOR (mammalian target of rapamycin) pathway shown in Figure 1.1. 
This pathway does not involve the neuronal synapse but instead is an intracellular pain 
pathway found in eukaryotes.  mTOR is an intracellular kinase that is made up of two 
individual compounds, mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2). 
mTOR has been shown to regulate cell growth and cell division, however, mTOR has 
also been implicated in the processing of pain. Several studies have found that the 
inhibition of mTOR results in decreased pain (Geranton, et al., 2009; Jiminez-Diaz et al., 
2008). Cui et al. (2014) found that neuropathic pain was decreased in rats when mTOR 
was inhibited. 
There are many inhibitors of mTOR and one such inhibitor is AMPK (5’ 
adenosine monophosphate-activated protein kinase) (Zoncu, Eleyan, & Sabatini, 2011). 
First discovered in 1973, AMPK was first found to play a role in the inhibition of fatty 
acid and cholesterol synthesis (Carlson & Kim, 1973).  In addition, AMPK has been 
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shown to play roles in exercise, appetite, aging, obesity, cardiovascular disease, cancer 
and neurological conditions (Steinberg & Kemp, 2009). Melemedjian et al. (2011) 
introduced the concept of AMPK playing a role in the pain pathway. This was further 
investigated by Tillu et al. (2012) who showed that activation of AMPK resulted in 
blockage of pain sensitization in mice.  In a review by Price and Dussor (2013), the 
concept of AMPK playing a possible role in the intervention of chronic pain was 
discussed. 
AMPK is activated when cellular energy levels are low and promotes catabolic 
cellular reactions, while inhibiting anabolic cellular reactions (Steinberg & Kemp, 2009). 
AMPK is activated via upstream kinases, LKB1 (liver kinase B1), CaMKK (calmodulin- 
dependent kinase kinase) and Tak1 kinase (transforming growth factor β-activated 
kinase-1) (Steinberg & Kemp, 2009). AMPK is also pharmacologically activated by 
AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) and novel compounds 
A769662 and OSU-53 in laboratory settings; by resveratrol, an antioxidant found in red 
wine; and by metformin, an FDA drug approved for the treatment of type 2 diabetes 
mellitus (Corton, Gillespie, Hawley, & Hardie, 1995; Ouyang, Parakhia, & Ochs , 2010). 
There are two main mechanisms by which AMPK inhibits mTOR (Figure 1.1). 
First, when AMPK is activated, it phosphorylates TSC2 (tuberous sclerosis protein 2 or 
hamartin), which inhibits Rheb, a GTP binding protein (Inoki, Kim, & Guan, 2012). 
When Rheb is inhibited, mTOR is not activated (Inoki et al., 2012). Secondly, AMPK 
also phosphorylates Raptor, a scaffolding protein that is a part of the mTORC1 portion of 
mTOR. When Raptor is phosphorylated, it inhibits mTORC1 (Inoki et al., 2012). 
Several factors can cause mTOR activation resulting in neuropathic pain (Figure 
1.1). First, increased glutamate release is seen in neuropathic pain (Kawamata & Omote, 
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1996). Glutamate is an excitatory neurotransmitter that activates the mTOR pathway via 
the m-Glu (metabotropic glutamate) receptor and the NMDA (N-methyl-D-aspartate) 
receptor (Hoeffer & Klann, 2010; Hou & Klann, 2004). Another mTOR activator is 
brain derived neurotrophic factor (BDNF) which is present in dorsal root ganglion 
neurons.  Cao, Byun, Chen, Cai, and Pan (2010) found increased BDNF activity in 
diabetic neuropathic-induced rats.  BDNF binds to TrkB (tropomyosin-related kinase B) 
receptors which activates the mTOR pathway (Nakamura et al., 2006).  Lastly, the 
mTOR pathway can be activated by substance P, a neuropeptide. Substance P activates 
the mTOR pathway via the NK1 (neurokinin-1) receptor (Mayordomo et al., 2012). 
Dauch, Yanik, Hsieh, Oh, and Cheng (2012) found increased substance P levels in 
diabetic neuropathic mice. 
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Figure 1.1  AMPK inhibition of mTOR signaling pathways.  Adapted from Hay and 
Sonenberg, 2004. 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Legend: 
AMPK 5’ adenosine monophosphate-activated protein kinase 
BDNF Brain derived neurotrophic factor 
m-Glu Metabotropic glutamate receptor 
mTOR Mammalian target of rapamycin 
NK-1R Neurokinin 1 receptor 
NMDA-R N-methyl-D-aspartate receptor 
Trk-B Tropomyosin-receptor kinase B 
TSC1  Tuberous sclerosis 1 
TSC2  Tuberous sclerosis 2 
P 
P   P 
P P 
Glutamate 
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1.5 Statement of the Problem 
 
Painful diabetic neuropathy affects anywhere from 8% to 26% of the diabetic 
population.  Pre-diabetic patients also suffer from chronic pain that is often eventually 
diagnosed as diabetic neuropathic pain.  Two of the three FDA approved medications to 
treat painful diabetic neuropathy have shown questionable efficacy and tolerability. The 
third medication, tapentadol, was just recently approved by the U.S. Food and Drug 
Administration (FDA) on August 28, 2012 to treat diabetic neuropathy.  These 
medications are pregabalin (Lyrica), duloxetine (Cymbalta) and tapentadol HCl (Nucynta 
ER).  Mechanistically, all three medications affect the neuronal synapse. 
Pregabalin reduces the release of excitatory neurotransmitters, glutamate and 
substance P by inhibiting voltage-dependent calcium channels (Field et al., 2006). 
Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI), which is thought 
to be the major mechanism of action (Koch et al., 2003).  Serotonin and norepinephrine 
are inhibitory neurotransmitters.  Tapentadol HCl was approved by the FDA in 2012 for 
the treatment of painful diabetic neuropathy.  Tapentadol HCl is a µ-opioid receptor 
agonist and norepinephrine reuptake inhibitor (Tzchenstke et al., 2007). This medication 
allows for the activation of the µ-opioid receptor which provides analgesic affects along 
with preventing reuptake of norepinephrine, an inhibitory neurotransmitter. 
The questionable efficacy and tolerability of pregabalin and duloxetine and the 
newness of Tapentadol HCl for the treatment of painful diabetic neuropathy and all three 
medication’s similarity in neuronal synapse mechanism, support the potential advantage 
of exploring an alternate intracellular pain alleviating medication. One such alternate is 
metformin.  As mentioned before, metformin activates AMPK.  Activation of AMPK 
inhibits mTOR which has been implicated in neuropathic pain. 
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This current investigation of metformin use in pain relief is novel in a human 
diabetic population, particularly a pre-diabetic population. Mao-Ying et al. (2014), has 
studied the possible effect of metformin and pain relief in a chemotherapy-induced 
peripheral neuropathic pain mouse model. This study showed that metformin has a 
neuroprotective effect which did protect against onset of pain. There is currently only 
one human study that has explored the possible use of metformin in chronic pain relief 
(Taylor et al.,2013) .  The condition studied was lumbar radiculopathy and metformin use 
was correlated with lower pain scores in this pain population. 
Even though the patients used in this study may have not been diagnosed with 
diabetic neuropathy, it is one of the more common chronic pain conditions associated 
with pre-diabetes and diabetes.  Therefore, diabetic neuropathy is the primary chronic 
pain condition mentioned in this study.  As will be discussed in Chapter 2, many chronic 
pain conditions have a similar mechanism involving the mTOR pathway.  Other chronic 
pain conditions such as lumbar radiculopathy, fibromyalgia and chemotherapy-induced 
neuropathy all activate the mTOR pathway resulting in chronic pain. The discussion of 
diabetic neuropathy is meant to give a background to the more common chronic pain 
condition associated with this pre-diabetic population. The overall objective of this study 
is not to assess metformin use on diabetic neuropathy but rather to gauge metformin’s 
correlation with pain scores in a chronic pain population. 
The problem investigated in this study was whether pain scores are lower in pre- 
diabetic patients on metformin than those on placebo. Also, the year by year pain scores 
were compared between the metformin and placebo groups.  In addition, we determined 
if there was a dose-response relationship between the dosage of metformin and pain 
severity rating. This was done by a retrospective analysis of data collected in the 
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Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study 
(DPPOS) by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK) of the National Institutes of Health (NIH).  These studies collected data from 
3,234 participants from over 27 clinical centers around the United States from 1996 to 
2008. 
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1.6 Hypothesis 
 
It was proposed that metformin therapy decreases pain based on previous studies 
that have shown that metformin inhibits mTOR via activation of AMPK (Inoki et al., 
2012; Ouyang, Parakhia, & Ochs, 2013).  mTOR activation has been implicated in pain 
(Geranton et al., 2009; Jimenez-Diaz et al., 2008).   The overall hypothesis was that pre- 
diabetic patients on metformin have lower pain scores (higher SF-36 BPS) than pre- 
diabetic patients on placebo. This retrospective descriptive data analysis of the 
association of metformin treatment and pain scores provides a rational basis for future 
prospective studies assessing metformin therapy for chronic pain disorders. 
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1.7 Purpose and Significance of the Study 
 
The overall purpose of the study was to evaluate the association of metformin 
therapy and pain scores in a pre-diabetic population. This was evaluated by comparing 
the SF-36 bodily pain scores of a pre-diabetic population on metformin versus a pre- 
diabetic population on placebo and also comparing the SF-36 bodily pain scores of a pre- 
diabetic population each year in both metformin and placebo groups. 
Current FDA approved medications for neuropathic pain associated with diabetes 
have shown questionable efficacy and tolerability (Dworkin et al., 2010).  All of these 
medications also have similar mechanisms in that all target areas of the neuronal synapse 
(Field et al., 2006; Koch et al., 2003; Tzchenstke et al., 2007).  These factors support the 
need and importance of exploring other possible pain relieving medications for painful 
diabetic neuropathy.  Metformin has been shown to decrease chronic pain in animal 
models and other chronic pain conditions.  The mechanism used by metformin is an 
intracellular mechanism.  Because of this different mechanism and much great 
tolerability, metformin is a medication that should be explored for its possible pain 
relieving properties. 
This study is significant in that, to date, no other study has explored the possible 
correlation between metformin use and pain scores in a pre-diabetic population. 
Although metformin therapy has been used for many years in the diabetic population to 
help control blood glucose levels, no study has investigated the possible correlation 
between metformin use and pain scores.  This study serves as a descriptive study based 
on existing data to examine this potential correlation. 
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1.8 Scope of the Study / Limitations of the Study 
 
This study is purely retrospective and will only determine whether a correlation 
exists between metformin therapy and pain scores in a pre-diabetic population. A 
correlation shown between metformin use and decreased pain scores does not indicate 
causation.  Further, although cellular and molecular signaling is a basis for the action of 
metformin, no direct measures of cellular signaling was done in this study. 
 
 
1.9 Methodology 
 
This was a descriptive, retrospective data analysis comparing pain scores of a pre- 
diabetic population on metformin or on placebo and also comparing pain scores of a pre- 
diabetic population before metformin therapy and at the end of metformin therapy using 
data from the Diabetes Prevention Program and Diabetes Prevention Program Outcomes 
Study.   The SF-36 Health Survey bodily pain score (SF-36 BPS) was used (Figure 1.2 
and Figure 1.3).  Bodily pain is measured from a score of 1 (none), 2 (very mild), 3 
(mild), 4 (moderate), 5 (severe) to 6 (very severe) and pain interference with work from a 
score of 1 (not at all), 2 (a little bit), 3 (moderately), 4 (quite a bit) to 5 (extremely) 
(Appendix A).  The raw scale scores are then entered into an algorithm which results in a 
scale between 0 – 100.  A score greater than or equal to 50 indicates normal or low bodily 
pain and a score less than 50 indicates higher bodily pain with increases in bodily pain as 
the score goes down (Hawker, Milan, Kendzerska, & French, 2011).  The SF-36 Health 
Survey for bodily pain has been validated as an instrument for measuring pain in a 
diabetic population (Jacobsen, De Groot, & Samson, 1993). The minimally important 
difference in the SP-36 BPS is three points (Ware et al., 2007). 
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Figure 1.2 SF-36 Measurement Model (Ware, 2000) 
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Figure 1.3 SF-36 Scales Measure Physical and Mental Components of Health 
(Ware, Kosinski, & Keller, 1994) 
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1.10 Summary 
 
Painful diabetic neuropathy affects people diagnosed with type 1 or 2 diabetes and 
pre-diabeties (Papanas et al., 2011; Ziegler, 2008).  Current FDA approved medications 
for painful diabetic neuropathy have had questionable efficacy and tolerability (Dworkin 
et al., 2010).  All of the approved medications have mechanisms which affect some 
aspect of the neuronal synapse.  Also, the latest approved medication, tapentadol HCl has 
only recently been approved for the treatment of painful diabetic neuropathy and, 
therefore, only a few studies have evaluated its efficacy.  For that reason, metformin 
therapy, with its intracellular pain inhibitory mechanism, high tolerability and low risk 
factor, should be explored for its possible correlation to pain scores in this patient 
population. 
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CHAPTER 2: REVIEW OF THE LITERATURE 
 
2.1 Overview 
 
Current pharmacological treatment of painful diabetic neuropathy include 
tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors, calcium 
channel blockers, topical lidocaine and narcotic pain medications such as tramadol and 
tapentadol HCl (Dworkin et al., 2010). Many of these treatments are used “off label” in 
that they are not officially approved for painful diabetic neuropathy.  In addition, some of 
the pharmacological treatments used for painful diabetic neuropathy, are used for 
treatment of other conditions (such as depression, sleep disturbances and fatigue) that co- 
exist with diabetic neuropathy. 
The three FDA approved medications for the treatment of painful diabetic 
neuropathy are pregabalin, duloxetine and tapentadol HCl. Many of the studies testing 
these medications have shown improvement in pain levels however, concerns have risen 
regarding their questionable efficacy and tolerability (Dworkin et al., 2010).  In addition, 
tapentadol HCl has only recently (2012) gained approval for treatment of diabetic 
neuropathy so the number of studies regarding its efficacy for diabetic neuropathic pain is 
limited. Tables 2.1, 2.2, 2.3 and 2.4 show the summaries of the studies from the last ten 
years of pregabalin, duloxetine and tapentadol HCl, along with studies of comparative 
and combination therapies involving duloxetine and pregabalin. 
The three approved medications for the treatment of painful diabetic neuropathy 
have mechanistic commonalities in that they all affect some aspect of the neuronal 
synapse.  Table 2.5 summarizes each approved medication.  Duloxetine is classified as a 
serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor (SNRIs). Duloxetine 
decreases the reuptake of serotonin and norepinephrine from the synaptic cleft back into 
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the presynaptic neuron.  Although the mechanism by which duloxetine works is unclear, 
besides reuptake inhibition it is thought to involve the alteration of the spinal 5-HT2A 
receptors (Mixcoatl-Zecuatl & Jolivalt, 2011).  Duloxetine allows more of these 
neurotransmitters to remain in the synaptic cleft.  Serotonin and norepinephrine are 
thought to help decrease pain as a result of causing pain inhibition from descending 
pathways of the brain and spinal cord (Millan, 2002).  Duloxetine was originally 
approved by the FDA in August 2004 for the treatment of depression and was approved 
for the treatment of diabetic neuropathic pain in September 2004.  It has since been 
approved for generalized anxiety disorder, major depressive disorder, fibromyalgia and 
chronic musculoskeletal pain. 
Pregabalin works by blocking voltage-gated calcium channels at the presynaptic 
neurons of the brain and spinal cord so that fewer excitatory neurotransmitters, such as 
glutamate and substance P, are released. Pregabalin works by binding to the Type 1 and 
2 α2 -δ subunits of voltage-gated calcium channels (Taylor, Angelotti, & Fauman, 2007). 
Pregabalin is derived from the neurotransmitter, amino butyric acid and was originally 
approved in the United States in 2004 for the treatment of partial seizures and 
neuropathic pain (including diabetic neuropathy).  In 2007, pregabalin was also approved 
for fibromyalgia pain. 
Tapentadol (Nucynta ER) is a narcotic pain medication that has a dual function of 
a μ-opioid receptor agonist and norepinephrine reuptake inhibitor (Vadivelu, Timchenko, 
Huang, & Sinatra, 2011). It has a weak affinity for the μ-opioid receptor which provides 
potent pain-relieving affects.  It also prevents norepinephrine reuptake which like 
duloxetine, allows for increase in norepinephrine allowing for increased pain inhibition. 
Tapentadol was first approved by the FDA in 2008 for the treatment of moderate to 
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severe acute pain.  In 2011, it was approved for the treatment of moderate to severe 
chronic pain and in 2012, it was approved for the treatment of neuropathic pain 
associated with diabetic peripheral neuropathy. 
As noted these three drugs approved for the pain relief of diabetic neuropathy, all 
work at the neuronal synapse.  These drugs have also shown mixed efficacy and have 
questionable tolerability and safety (Dworkin et al., 2010). Vranken et al. (2011) showed 
that duloxetine had no significant effect in pain intensity in patients with central 
neuropathic pain. Moore, Straube, Wiffen, Derry, & McQuay (2010) reviewed several 
randomized clinical trials of pregabalin for acute and chronic pain and found that a 
majority of patients found little or no pain relief on pregabalin or will discontinue use due 
to adverse effects. Desai et al. (2014) did a systematic review of studies regarding 
treatment of diabetic neuropathy with tapentadol and found that there was a high 
incidence of discontinuation of tapentadol due to adverse side effects.  In addition, 
neuropathic pain does not respond well to opiates, thus limiting the affect that tapentadol 
may have in diabetic neuropathic pain (Chakravarty & Sen, 2010). 
Therefore, it is important that alternate pain alleviating mechanisms be explored 
in treating diabetic neuropathic pain.  One such possibility is the drug, metformin. 
Unlike the other drugs currently approved for painful diabetic neuropathy, metformin has 
a high safety profile and tolerability.  Literature leading to a possible alternative pain 
alleviating mechanism involving metformin therapy in the diabetic neuropathic 
population will be reviewed. Note that the literature on cellular and molecular 
mechanisms is exclusively from preclinical animal models. 
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Table 2.1 Research studies of pregabalin in patients with painful diabetic 
neuropathy for the last ten years 
 
Study Results Pain 
Scale 
Raskin et al. 
(2014) 
At the end of the double blind phase, no significant 
difference was found between pregabalin and placebo in 
the primary endpoint of mean pain score. 
NRS 
Razazian et al. 
(2014) 
Double-blind parallel clinical trial randomized to 
carbamazepine, venlafaxine or pregabalin. Pregabalin 
shown to be superior to the other two drugs in pain 
reduction. 
VAS 
Vasudevan, Naik, 
& Mukaddam 
(2014) 
Open label, randomized, parallel group study of 
combination therapy of methylcobalamin, alpha lipoic acid 
and pregabalin versus just pregabalin.  Significant 
improvement in pain in both groups.  No significant 
difference noted between groups. 
NRS 
Patel, N., Mishra, 
Patel, P., 
& Dikshit (2014) 
Prospective observational study of patients on 
carbamazepine, pregabalin or alpha lipoic acid therapy. 
The pregabalin group had the best reduction in pain. 
VAS 
Satoh et al. 
(2011) 
Randomized double blind placebo controlled study of 
patients on pregabalin or placebo.  Pregabalin shown to 
reduce pain. 
SF-MPQ, 
VAS 
Bansal, Bhansali, 
Hota, 
Chakrabarti, & 
Dutta (2009) 
Randomized, double blind study of patients on varying 
doses of amitriptyline or pregabalin.  Some type of pain 
relief was seen in both therapies. 
McGill’s 
Likert 
Arezzo, 
Rosentock, 
Lamoreaux, & 
Pauer (2008) 
Randomized, double blind, placebo controlled study of 
patients treated with pregabalin (600 mg/d) versus 
placebo. Patients on pregabalin had reduction in pain. 
Mean pain 
score (11-
pt scale) 
Baron, 
Brunnmuller, 
Brasser, May, & 
Binder (2008) 
Prospective, open label, non-controlled study of patients 
with diabetic peripheral neuropathy or postherpetic 
neuralgia treated with pregabalin.  Patients shown 
improvement in pain. 
11-pt 
numerical 
scale 
Tolle, 
Freynhagen, 
Versavel, 
Trostmann, & 
Young (2008) 
Randomized, double blind placebo controlled study of 
patients on placebo or 150, 300, 600 mg/d pregabalin. 
Pain scores for patients on 600 mg/d pregabalin were 
significantly improved. 
NRS (11- 
pt scale) 
Richter et al. 
(2005) 
Randomized, double blind study of patients on placebo or 
pregabalin (150 or 600 mg/d). Patients on pregabalin 600 
mg/d showed significant reduction pain scores. 
VAS or 
the SF- 
MPQ 
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Table 2.2 Research studies of duloxetine in patients with painful diabetic 
neuropathy for the last ten years 
 
Study Results Pain Scale 
Kaur et al. 
(2011) 
Randomized, double-blind, crossover trial of patients 
receiving amitriptyline or  duloxetine for 6 weeks and then 
a placebo washout period for 2 weeks followed by the 
amitriptyline group receiving duloxetine and vice versa. 
Similar improvement in pain scores in both drugs were 
seen. 
VAS (1- 
100) 
Yasuda et al. 
(2011) 
Randomized, double-blind, placebo controlled study in 
patients on duloxetine (40 mg or 60 mg/day) or placebo. 
Duloxetine patients showed a reduction in pain scores 
compared to placebo. 
BPI 
Gao et al. 
(2010) 
Double-blind, randomized, placebo-controlled study with 
patients on duloxetine (60 to 120 mg) or placebo.  No 
significant difference seen at end point. 
BPI 
Skljarevski et 
al. (2009) 
Open label study of patients on duloxetine (60 mg QD) for 
8 weeks. Responders continued on this dose while non- 
responders placed on 120 mg.  Pain reduction was 
observed (50% in responders and 31.8% in non- 
responders). 
BPI 
Armstrong et al. 
(2007) 
Double-blind study of patients on duloxetine (20 mg/d, 60 
mg/d or 60 mg/bid) or placebo.  Duloxetine 60 mg/d and 
60 mg/bid superior to placebo. 
SF-36 
and BPI 
Wernicke et al. 
(2007) 
Extension of the 2006 Wernicke et al study to lengthen the 
time. Duloxetine was still better than routine care in 
decreasing bodily pain scores. 
SF-36 
Wernicke et al. 
(2006a) 
Double-blind study of patients assigned to duloxetine 60mg 
QD or duloxetine 60 mg BID or placebo for 12 weeks. 
Management of pain was seen in both doses of duloxetine 
over placebo. 
Likert scale 
(11- 
point) 
Wernicke et al. 
(2006b) 
Parallel, double-blind randomized, placebo-controlled 
study of patients on duloxetine or routine care.  Duloxetine 
was better than routine care in decreasing bodily pain 
scores. 
Likert scale 
(11- 
point) 
Raskin et al. 
(2005) 
Parallel, double-blind, randomized, placebo-controlled 
study assigned to duloxetine (once or twice daily) or 
placebo.  Both duloxetine groups showed improvement in 
pain scores. 
Likert scale 
(11- 
point) 
Goldstein, Lu, 
Detke, Lee, & 
Iyengar (2005) 
Double-blind study of patients assigned to duloxetine (20, 
60 or 120 mg) or placebo. Duloxetine (60 and 120mg) 
showed significant greater improvement than placebo. 
Likert scale 
(11- 
point) 
23  
Table 2.3 Research studies of tapentadol HCl in patients with painful diabetic 
neuropathy 
 
Study Results Pain Scale 
Niesters et al. 
(2014) 
Randomized, double-blind, placebo controlled study of 
patients on tapentadol SR or placebo. Significant pain relief 
seen in tapentadol patients. 
NRS and 
VAS 
Vinik et al. 
(2014) 
Double-blind, placebo controlled, randomized study of 
patients on placebo versus a new formulation of Tapentadol 
ER.  Tapentadol was effective for the management of 
neuropathic pain. 
NRS 
(Likert 
type) 
Schwartz et al. 
(2011) 
Double-blind, placebo controlled, randomized study of 
patients on placebo versus tapentadol.  Tapentadol provided 
a significant decrease in pain. 
NRS 
 
 
Table 2.4 Research studies of pregabalin, duloxetine, comparison and combination 
therapies in patients with painful diabetic neuropathy for the last ten years 
 
Study Results Pain Scale 
Happich et al. 
(2014) 
Prospective, non-interventional study of patients on 
duloxetine, pregabalin or gabapentin. All pain scores 
decreased on all medications with the duloxetine being the 
biggest decrease.  However, the dosing of pregabalin and 
gabapentin was lower than duloxetine. 
BPI 
Tesfaye et al. 
(2013) 
Randomized, double-blind parallel study of patients on 
combination duloxetine and pregabalin therapy or max dose 
of duloxetine or pregabalin therapy. There was no significant 
difference among therapies regarding average pain. 
BPI 
Boyle et al. 
(2012) 
Double-blind, randomized parallel study in which patients 
were randomized into pregabalin, amitriptyline or duloxetine 
group.  All treatment groups showed decreases in pain with 
no one treatment superior to the others. 
BPI 
Devi et al. 
(2012) 
Prospective, randomized open label study of patients on 
gabapentin, duloxetine or pregabalin.  All three groups had 
reductions in pain scores with no differences among the 
groups. 
VAS 
Tanenberg et al.  
(2011) 
Open-label study of patients randomized to duloxetine, 
pregabalin or combination of duloxetine and gabapentin. No 
significant difference in pain reduction found between 
duloxetine and pregabalin. 
BPI 
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Table 2.5 Summary of Approved Diabetic Neuropathy Medications 
 
Medication Classification Year Approved by FDA 
for Diabetic Neuropathy 
 
Duloxetine (Cymbalta) 
 
Serotonin (5-HT) and 
norepinephrine (NE) reuptake 
inhibitor (SNRI) 
 
 
2004 
 
Pregabalin (Lyrica) 
 
Anticonvulsant 
 
2004 
 
Tapentadol (Nucynta) 
 
Opioid 
 
2012 
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2.2 Historical Background 
 
One of the earliest recorded cases regarding pains associated with diabetes was 
made in 1798 when physician John Rollo of Britain, described several cases of pains in 
patients diagnosed with diabetes (Rollo, 1798).  In 1885, William Pavy made an 
introductory address regarding diabetes in which he described in detail, the painful 
symptoms exhibited by diabetic patients in his care (Pavy, 1885).  In his address, he 
mentions that the pains appear to be spinal and that there must be an association between 
the neural symptoms and pain. He also uses the term “hyperaesthesia” to describe what 
we now refer to as hyperalgesia. 
In 1887, T. Davies Pryce described what he found to be a degeneration of the 
peripheral nerves of a diabetic patient suffering from ulcers of the feet. He attributed this 
degeneration to “diabetes and vascular disease.”  Walter M. Kraus (1922) wrote a 
synopsis regarding studies concerning the pathology of the neurologic symptoms of 
diabetes.  There was much debate in the scientific community regarding whether the 
pathology of diabetic neuritis (now referred to as neuropathy) was a result of lesions in 
the spinal cord or lesions in the peripheral nerves.  In this report, he believes that the 
neuropathy is a result of a spinal cord pathology and not a result of damage to the 
peripheral neurons.  However, in 1929, Woltman and Wilder compiled a summary of 10 
case studies in which neurological tissues of patients with painful diabetic neuropathy 
were examined.  All the studies showed signs of degeneration and lesions of the 
peripheral nerves and spinal cord. 
In 1953, Hirson, Feinmann, and Wade, used the term diabetic neuropathy to 
include all diabetic patients that undergo some kind of changes to the neurons in which 
there are no other explanations for their neurological symptoms. He describes that the 
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hyperglycemia results in “irritation, inflammation and degeneration” of the nerves. He 
also lists pain as being “the most important clinical manifestation of active diabetic 
neuropathy.” 
In 1955, Allan Bailey wrote about the involvement that the nervous system must 
play in diabetic neuropathy.  He proposed that diabetic neuropathy should be divided into 
those that are a result of “disturbed metabolism” and vascular alterations due to diabetes. 
As far as the diffuse pain associated with diabetic neuropathy, he suggests that it is “due 
to some metabolic disturbance associated with poor control of diabetes.” 
Pain associated with diabetes has also been seen in patients with impaired glucose 
tolerance (now referred to as pre-diabetes, a term first officially introduced by Jerome 
Conn in 1958).  This observation has led to the current practice that people with 
idiopathic painful neuropathies that have not been diagnosed with diabetes, should be 
evaluated for pre-diabetes (Russell & Feldman, 2001).  Studies by Murakawa et al. 
(2002), Novella, Inzucchi, and Goldstein (2001), Sahin et al. (2008), and Singleton, 
Smith, and Bromberg (2001), have shown the association of impaired glucose tolerance 
and painful neuropathy.  These studies have led to the conclusion that painful neuropathy 
associated with diabetes may initiate before the official diagnosis of diabetes. 
One of the earliest studies regarding a possible drug therapy for diabetic 
neuropathy was published in 1969 by Rull, Quibrera, Gonzalez-Millan, and Lozano 
Castaneda.  In this double blind crossover study, patients were assigned to either a 
carbamazepine (Tegretol) group or a placebo group. Carbamazepine is an anticonvulsant 
and was initially found to relieve neuropathic pain associated with trigeminal neuralgia.  
Although pain relief was seen in 28 of the 30 patients with carbamazepine treatment, 
there were troublesome side effects associated with its use. Many other studies have 
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followed regarding possible treatments for painful diabetic neuropathy.  These studies 
have ranged from vitamin therapy to transcutaneous electrical stimulation. However, 
most pharmaceutical therapies have focused on antidepressants and anticonvulsants, such 
as duloxetine and pregabalin. 
Despite the plentiful case studies regarding painful diabetic neuropathy, the 
mechanisms by which the pain originates is not completely agreed upon.  What can be 
agreed upon is that there are abnormalities of the peripheral and central nervous system. 
Diabetes causes damage to the peripheral nerves resulting in hyperexcitability or 
sensitization of the neurons.  This causes an increase in activation of sodium and calcium 
channels of which results in increased release of the excitatory neurotransmitters, 
substance P and glutamate (Aslam, Singh, & Rajbhandri, 2014; Veves, Backonja, & 
Malik, 2008). 
One possibility that may explain the increase in activity of sodium channels 
(particularly Nav1.8) in pain signaling neurons may be linked to the metabolite, 
methylglyoxal (Bierhaus et al., 2012).  Methylglyoxal formation is a result of increased 
glycolysis.  Type 2 diabetic patients have shown an increase in methylglyoxal and the 
amount of increase is correlated to the severity of pain (Bierhaus et al., 2012).  In 
Bierhaus’ study (2012), it was shown the methylglyoxal causes post-translational 
modification of the Nav1.8 channel which resulted in increased neuronal excitability. 
Methylglyoxal also slows inactivation of the Nav1.7 channel. 
The Cav3.2 isoform of the T-type calcium channel current shows an increase in 
amplitude in the neurons of mice with diabetic neuropathy (Jagodic et al., 2007).  The 
increase in amplitude of these calcium channels amplifies the pain signals of the neurons. 
This T-type calcium channel has been shown to be upregulated in diabetic neuropathic 
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mice models (Takahashi et al., 2010).  It is known that activation of these channels are 
implicated in nociceptive signaling (Todorovic & Jevtovic-Todorovic, 2013). 
These studies have shown the importance that these sodium and calcium channels 
play in the development of diabetic neuropathic pain. Any drugs that would target these 
channels would work extracellularly, which is a similarity shared with the current 
approved therapies.  The proposed metformin therapy would target an intracellular 
pathway which is a novel way of helping to relieve diabetic neuropathic pain. 
Metformin (dimethylbiguanide) is derived from Galega officinalis, commonly 
known as French lilac (Bailey & Day, 2004). Guanidine, its derivative, was used as a 
glucose lowering drug in early Europe. Metformin was approved for use in the United 
States in 1995.  It prevents high glucose levels by reducing the rates of gluconeogenesis 
and glycogenesis in the liver and it also suppresses beta oxidation (Krentz & Bailey, 
2005). Because of its high tolerability, low side effects and efficacy in lowering blood 
glucose, it has become one of the most widely used oral drugs for the treatment of 
diabetes and pre-diabetes.  Metformin also readily crosses the blood brain barrier, which 
is of importance for this study (Labuzek et al., 2010). Although the exact molecular 
mechanisms behind the glucose lowering effects of metformin have yet to be determined, 
Zhou et al. (2001) has shown in rat models that metformin causes the intracellular 
activation of AMPK.  It is this activation of AMPK by metformin resulting in the 
inhibition of mTOR that may lead to a decrease in pain. 
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2.3 Potential Cellular and Molecular Mechanisms 
 
2.31 mTOR Pathway, Pain and Central Sensitization 
 
mTOR is a serine-threonine kinase found in all eukaryotic cells.  It is known to 
play a role in protein synthesis, cell proliferation and growth.  Recently, it has been 
shown to be involved in the pain mechanism and synaptic plasticity.  In particular, mTOR 
has been implicated in chronic but not acute pain states (Geranton et al., 2009). Cui et al. 
(2014) found that the mTOR pathway played a role in the rat neuropathic pain model. 
The suspected mechanism underlying mTOR and pain is the fact that mTOR activation 
leads to a suppression of potassium channel Kv1.1 in the dendrites of sensory neurons 
(Raab-Graham, Haddick, Jan, Y., & Jan, L., 2006). This suppression of Kv1.1 by mTOR 
increases the excitability of the sensory neurons (Chi & Nicol, 2007).  In addition, 
research has shown that the mTOR pathway also plays a role in central sensitization 
(Gregory, E., Codeluppi, Gregory, J., Steinauer, & Svensson, 2010; Jimenez-Diaz, et al., 
2008; Shih, Kao, Wang, Yaster, & Tao, 2012). Central sensitization is a suspected 
mechanism underlying painful diabetic neuropathy. 
Central sensitization occurs when nociception in the central nervous system is 
markedly increased.  This results in pain from non-painful stimuli (allodynia) and 
increased response to painful stimuli (hyperalgesia). Central sensitization also results in 
hypersensitivity to pain as well as amplification of pain.  Central sensitization has been 
shown to occur following peripheral nerve injury and hypoxia (Burchiel, 1984; Devor & 
Wall, 1990). Central sensitization results in increased release of glutamate and substance 
P, which are excitatory neurotransmitters (Khasabov et al., 2002; Li, W., Wang, & Li, H., 
2014; Moochhala & Sawynok, 1994). Brain derived neurotrophic factor (BDNF) is also 
released when sensory fibers are activated (Geng et al., 2010; Lever et al., 2001). 
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Glutamate, substance P and BDNF are increased in neuropathic pain. (Cao et al., 2010; 
Dauch, Yanik, Hsieh, Oh, & Cheng, 2012; Kawamata & Omote, 1996).   Glutamate, 
substance P and BDNF set in motion various downstream targets that eventually results 
in activation of the mTOR pathway. 
When glutamate activates group I metabotropic glutamate receptors (mGluRs) 
and N-methyl-D-asparate (NMDA) receptors, it initiates the phosphatidylinositol 3-kinase 
(PI3K) signaling pathway.  Activation of PI3K results in a cascade of events triggering 
phosphoinositide-dependent kinase 1 or 2 (PDK 1/2), Akt (also called protein kinase B – 
PKB) and then mTOR (Klann & Dever, 2004).  Substance P works in a similar manner in 
that when it binds to neurokinin 1 receptor (NK1R), it activates the PI3K-PDK 1/2-Akt- 
mTOR signaling pathway (Xu et al., 2011).  BDNF also activates the PI3K-PDK 1/2 – 
Akt-mTOR pathway when it binds to tropomyosin receptor kinase B (TrkB) receptor 
(Troca-Marin, Alves-Sampaio, & Montesinos, 2011). Figure 1.1 in Chapter 1 shows 
these mechanisms.  An additional mechanism of BDNF - mTOR activation - has also 
been proposed by Briz et al. (2013), in which calpain-2, a calcium-dependent cysteine 
protease, further stimulates the PI3K-PDK 1/2-Akt-mTOR pathway. 
mTOR has also been indicated in long term potentiation (LTP).  LTP is related to 
central sensitization in that LTP is one suspected mechanism behind nociceptive 
sensitization in the dorsal horn of the spinal cord.  LTP involves the increase of synaptic 
receptors over time due to repeated release of excitatory neurotransmitters at the synapse. 
Therefore, upon repetition of nociceptive signaling, the overload of excitatory 
neurotransmitters results in an increase of synaptic receptors over time. Kelly, Crary, and 
Sacktor (2007) showed that inhibition of mTOR blocked protein kinase M zeta which has 
been shown to maintain LTP. Activation of protein kinase M zeta has been proven to 
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maintain persistent pain states (Asiedu et al., 2011; Li et al., 2011; Marchand et al., 
2011).  Thus, inhibition of mTOR leads to decreased synthesis of protein kinase M zeta 
and, in turn, LTP of nociceptive sensitization is not maintained. 
2.32 AMPK and the mTOR pathway 
 
AMPK (5’ adenosine monophosphate-activated protein kinase), an intracellular 
eukaryotic kinase consisting of three subunits (α, β and γ), is known to play an important 
role in metabolism (Hardie, Hawley, & Scott, 2006). AMPK was first discovered in 1973 
when it was found to play a role in inhibition of fatty acid and cholesterol synthesis 
(Carlson & Kim, 1973).  AMPK is often called the energy sensor of the cell because it is 
activated when levels of ATP (adenosine triphosphate) are low. When activated, AMPK 
turns off energy consuming process in the cell and turns on energy producing processes. 
Besides its role in carbohydrate, lipid and protein metabolism, AMPK has been 
found to play a role in aging, obesity, cardiovascular disease, cancer and neurological 
conditions (Steinberg & Kemp, 2009).  The large body of recent research has focused on 
AMPK’s role in cancer, cardiovascular disease and obesity. However in 2011, 
Melemedjian et al. introduced the concept of AMPK playing a role in neuropathic pain 
conditions.  This study hypothesized that AMPK may have a potential effect on neuron 
excitability. Nerve injury was induced in mice and rats.  Enhanced mTOR activation was 
seen in those rodent models that had induced nerve injury.  AMPK was then activated in 
these mice and mTOR phosphorylation decreased. With the decrease of mTOR, 
excitability of the sensory neurons also decreased.  This study led to the conclusion that 
activation of AMPK decreased phosphorylation of mTOR which “led to a full reversal of 
neuropathic allodynia.” (Melemedjian et al., 2011) 
The mechanism for AMPK inhibition of mTOR was investigated by Inoki et al. 
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(2012). Activation of AMPK results in phosphorylation of TSC2, which inhibits Rheb, 
thereby preventing mTOR from being activated. AMPK activation also phosphorylates 
Raptor, which inhibits mTORC1, one of the components of mTOR. 
2.33 Metformin and AMPK 
 
Metformin is a drug widely used for the treatment of type 2 diabetes mellitus and 
metabolic syndrome (insulin resistance, pre-diabetes).  Although all the mechanisms 
underlying metformin actions in the treatment of diabetes remain uncertain, metformin 
has been shown as an indirect activator of AMPK.  In 2010, Ouyang et al. determined 
that metformin activation of AMPK is through the inhibition of AMP deaminase. By 
inhibiting AMP deaminase, AMP levels increase in the cell. This increase in AMP levels 
causes phosphorylation and activation of AMPK. 
2.34 Pain and Metformin 
 
In the Melemedjian et al. study (2011), some of the nerve injured mouse models 
were then treated with metformin (200 mg/kg/day) for seven days. These metformin 
treated mice showed a complete reversal of pain symptoms that were induced by the 
nerve injury. Upon analysis of the nerve tissue, the metformin treated mice showed a 
decrease in the phosphorylation of mTOR. This decrease was metformin dose dependent. 
In a single case observation Labuzek, Liber, Marcol, and Okopien (2012) and 
Labuzek, Liber, Suchy, and Okopien (2013) noticed decreased pain in a patient upon 
administration of metformin.   The patient was diagnosed with Decrum’s disease and had 
pain scores of 8/10, 6/10 and 7-8/10 during the initial visit, during the previous week, and 
over the previous month.  The patient was diagnosed with type 2 diabetes mellitus and 
metformin therapy (starting at 2550 mg a day and increased to 3,000 mg a day) was 
initiated.  Pain scores were then evaluated three times during the following month on 
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metformin therapy and the pain scores were 1-2/10, 1/10 and 1-2/10. 
Russe et al. (2013) showed that activation of AMPK with AICAR and metformin 
elicited anti-inflammatory and anti-nociceptive effects in mouse models similar to that of 
ibuprofen.  Taylor et al. (2013) published a retrospective chart review on patients with 
lumbar radiculopathy.  Pain outcomes were compared in 46 patients on metformin and 94 
patients not on metformin.  Pain questionnaires were given to patients upon initial visit to 
a pain specialist.  Metformin use was associated with a decrease in lumbar radiculopathic 
pain. This seminal study provides compelling rationale for my hypothesis that metformin 
therapy will be correlated to decreased pain scores in pre-diabetic patients. 
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2.4 Review of Similar Studies 
 
Mao-Ying et al. (2014) showed that metformin decreased chemotherapy-induced 
neuropathic pain in mice models.  Cancer patients develop pain, numbness and tingling in 
the hands and feet as a result of chemotherapy treatment.  In this study, metformin 
therapy or saline was given to mice seven days before administration of the 
chemotherapy drugs, cisplatin or paclitaxel. The hind paw withdrawal response using the 
Von Frey test was used to measure mechanical allodynia. Administration of metformin 
almost completely prevented mechanically induced pain normally seen with cisplatin and 
paclitaxel administration. The study also concluded that metformin also had a 
neuroprotective effect by reducing loss of peripheral nerve endings. 
Taylor et al. (2013) did a retrospective chart review of patients diagnosed with 
lumbar radiculopathy.  Patients diagnosed with lumbar radiculopathy were given a pain 
questionnaire upon their initial to a pain specialist.  In this questionnaire, pain 
characteristics, current pain, total overall pain and pain effect on daily life was examined. 
Electronic health records were used to perform a chart review of these patients and 
treatment of the patients with metformin was noted. 
There were 94 patients who served as controls and 46 patients who met the 
metformin group criteria.  The onset of pain did not differ between the groups, however, 
the patients on metformin therapy did report a considerably reduced current pain score. In 
addition, many of the other pain characteristics showed a decrease in the metformin 
group. 
Russe et al. (2013) showed that it is the activation of the catalytic α2 subunit of 
AMPK by metformin or AICAR that may be responsible for the anti-inflammatory and 
anti-nociceptive effects.  Nociception and inflammation was induced by formalin or 
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zymosan injected into the hind paws of mice.  AMPK was then activated by 
administration of metformin or AICAR. Another group of mice were given ibuprofen 
instead of metformin or AICAR. 
The treatment of the mice by metformin or AICAR showed significant decreases 
in nociceptive response similar to treatment by ibuprofen. To determine what subunit of 
AMPK is activated by metformin and AICAR, AMPKα2 knockout mice were subjected 
to the same protocol. The absence of anti-nociceptive and anti-inflammatory effects in 
these knockout mice provide very compelling evidence for the role of AMPK. 
Labuzek et al. (2013) noted in a case report of a patient with Decrum’s disease 
that administration of metformin significantly reduced pain intensity.  Decrum’s disease, 
also known as lipomatosis dolorosa or adiposis dolorosa, is an extremely rare disorder 
that results in many painful lipomas.  The patient was newly diagnosed with type 2 
diabetes and therefore was placed on metformin therapy. Unpredictably, the patient post- 
metformin therapy, showed a phenomenally reduced intensity of pain scores from nine to 
three following four months of metformin therapy. 
Tiliu et al. (2012) studied the activation of AMPK by resveratrol and found that 
AMPK activation resulted in decreased signaling in sensory neurons which resulted in 
decreased acute pain and decreased chronic pain.  In the study, mice were assessed for 
paw withdrawal thresholds.  Incisions were made on the mice. The mice then received an 
injection of resveratrol.  After recovery, paw withdrawal thresholds were measured at 
different time periods post surgery.  Some of the mice were also given injections of IL-6 
(interleukin-6) or PGE2 (prostaglandin E2) with and without resveratrol. The IL-6 served 
to simulate acute sensitization and PGE2 serves to simulate persistent sensitization. 
Trigeminal ganglion (TG) neurons from the mice were removed and exposed to 
36  
increasing concentrations of resveratrol at different time points. Also to test whether or 
not resveratrol’s activation of AMPK was Sirt1 dependent, a Sirt1 inhibitor was applied. 
The TG neurons were also treated with resveratrol and IL-6. 
Several significant findings occurred in the incision-induced mice.  First, was 
that resveratrol activates AMPK and this activation suppressed ERK and mTOR 
signaling. 
This activation was dose and time dependent.  Second, IL-6 pain induction was reduced 
by resveratrol.  Third, incision induced allodynia was inhibited by resveratrol.  Fourth, 
resveratrol blocked chronic nociceptive sensitization. 
This study was the first to show that activation of AMPK resulted in suppression 
of ERK and mTOR signaling which leads to inhibition of not only acute pain but also 
chronic pain states.  It also showed that activation of AMPK may be a novel way of 
treating acute and chronic pain. 
Melemedjian et al. (2011) showed that activation of AMPK by metformin and 
A769662 inhibited protein synthesis in nerve injured rats and mice which resulted in 
decreased neuropathic pain.  Spinal nerve ligation was done on rats and paw withdrawal 
thresholds were measured.  Rats were given metformin or A7969662 (an investigational 
compound) and paw withdrawal thresholds were done again. The sciatic nerves of the 
rats were then excised for analysis. Mouse trigeminal ganglia were also excised and 
analyzed. 
The nerve injury stimulated restructuring of the translational processing in the 
sensory neuron.  By analyzing the mouse trigeminal ganglia, it was found that metformin 
activated AMPK and AMPK inhibited the mTOR pathway but did not affect the ERK 
pathway.  Metformin influenced the mTOR pathway by inhibiting the eIF4F complex 
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formation.  eIF4F is a protein that brings the mRNA to the ribosome for translation. This 
inhibition of translation also decreased the excitability of the sensory neurons. This “led 
to full reversal of neuropathic allodynia.” 
This study is significant in that it showed that metformin administration inhibits 
the mTOR mechanism. This inhibition in the mTOR mechanism decreased excitability 
of the sensory neurons injured by spinal nerve ligation. Therefore, administration of 
metformin resulted in decreased neuropathic pain.  This study also showed that how 
metformin works to decrease pain is through inhibition of the mTOR pathway and not the 
ERK pathway. 
Obara et al. (2011) subjected mice to peripheral nerve injury, local inflammation 
by injection of carrageenan and mechanical hypersensitivity by injection of capsaicin. 
Cold stimulation was also done using the acetone test and heat stimulation was also 
tested. Some of the mice were given injections of CCI-779 (temsirolimus) or Torin1 
which are both mTOR inhibitors.  Paw withdrawal thresholds in all mice were measured. 
The skin from the hind paw around the foot pads and the dorsal roots were dissected out 
to be analyzed for mTOR and p-mTOR (phosphorylated mTOR).  Lumbar dorsal spinal 
cord and dorsal roots were also removed after injections of CCI-779/Torin1. 
Mice that received injections of CCI-779 showed reduced mechanical and cold 
hypersensitivity by inhibiting mTORC1 in the spinal cord and dorsal roots.  CCI-779 
injection was also shown to decrease mTORC1 activity in the hippocampus. However, 
injection of CCI-779 did not affect glial or cytokine activity.  Unlike CCI-779 which 
only inhibits mTORC1, Torin1 inhibits both mTORC1 and mTORC2. Administration 
of Torin1 produced similar results as CCI-779 in that it reduced mechanical and cold 
hypersensitivity after nerve injury. 
38  
This study shows that inhibition of mTOR results in inhibition of mechanical and 
cold hypersensitivity.  It also shows that inhibition of mTORC1 alone results in decreased 
hypersensitivity.  This further supports the idea that the mTOR pathway plays an 
important role in nociception and may be the key to controlling chronic pain. 
Asante, Wallace, and Dickenson (2010) studied mTOR activity in deep dorsal 
horn spinal neurons in rats.  Just as in the other studies, spinal nerve injury was induced 
in the treatment group, cold hypersensitivity was invoked using acetone and paw 
withdrawal tests were performed.  In this study CCI-779 was used to inhibit mTOR. 
After electrophysiology testing, the parts of the spinal cord at the level at L4, L5 and L6 
was removed and analyzed for mTOR. As in the more recent studies, inhibition of mTOR 
was shown to reduce mechanically induced hypersensitivity.  However, what makes this 
study unique is the result that mTOR signaling plays an important role in neuronal 
plasticity, which could result in chronic pain hypersensitivity and central sensitization. 
This could be a key factor in persistent pain states. 
 
Geranton et al. (2009) showed that inhibition of the mTOR pathway affected 
chronic pain states but not acute pain states.  mTOR was inhibited in rats by 
administration of rapamycin.  Inhibition of mTOR resulted in decreased spread of the 
pain signaling to undamaged neural tissues in addition to reducing mechanical pain 
sensitivity.  This study also showed the mTOR is widely present in myelinated A-fibers 
but only present in very few C-fibers. The significant finding of this study is that 
inhibition of mTOR resulted in decreased afferent sensitivity and decreased central 
plasticity. 
Jimenez-Diaz et al. (2008) showed that the mTOR pathway exists in neuronal 
sensory fibers. mTOR has long been shown to play a role in neural plasticity and 
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memory.  This study examined whether or not the mTOR pathway plays a role also in 
sensory neurons.  The results show that the mTOR pathway is active in A-fibers but only 
in a certain small population of C-fibers.  Because the mTOR pathway is associated with 
protein translation, inhibition of this pathway resulted in decreased central amplification 
of pain. 
40  
2.5 Need for the Study 
 
No study has investigated the correlation that metformin has with pain scores in a 
pre-diabetic population.  Studies regarding metformin administration have shown 
decreased pain.  Taylor et al. (2013) and Labuzek et al. (2013) have shown a correlation 
between metformin use and decreased pain in human populations but most studies 
regarding metformin and decreased pain have been done in animal models. No study to 
date has explored the correlation between metformin and pain in human pre-diabetic 
patients.  This study will explore whether administration of metformin, a widely used 
FDA drug already approved for type 2 diabetes mellitus, is correlated with decreased pain 
scores in a pre-diabetic population. 
In addition, this study proposes an alternate medication for relieving chronic pain 
in a pre-diabetic population. Three current FDA approved medications for painful 
diabetic neuropathy include an SNRI, an anticonvulsant and an opioid. This study 
focuses on metformin’s possible correlation in pain relief.  Because of the questionable 
efficacy and decreased tolerability of the FDA-approved medications, it is of utmost 
importance that other pain mechanisms be explored in this pain population. 
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2.6 Confounding Variables 
 
Several variables could affect self-report pain scores. Most variables that could 
affect pain scores were controlled by the exclusion criteria of the study.  However, there 
are variables that could affect self-reporting of pain scores. These variables are gender, 
age, race and BMI (body mass index). Several studies have shown that these variables 
may have an effect on self-reported pain scores. 
Green et al. (2003) did a literature review on studies pertaining to emergency pain 
care, postoperative pain, cancer pain and chronic nonmalignant pain and whether racial 
and ethnic disparities existed with regards to pain perception, assessment and treatment. 
The results of this study found racial and ethnic disparities in all categories regarding 
pain. 
Krueger and Stone (2008) conducted a telephone-based survey of 3,982 people 
and asked them to rate their pain from zero to six. The results of the study showed that 
average pain ratings increased with age.  Interestingly, however, they found little 
differences in the average pain ratings between males and females. 
Hitt, McMillen, Thornton-Neaves, Koch, and Cosby (2007) did a cross-sectional 
study to assess the correlation between obesity and self-reported pain.  Using data from 
the Southern Pain Prevalence Study in 2004, Hitt et al. found that adults with a BMI 
greater than 30 experienced more pain than adults with BMI less than 30.  In addition, as 
the BMI increased, their average pain increased. 
Raftery, Smith-Coggins, and Chen (1995) conducted a prospective cohort study in 
which participants who arrived in the emergency department with a headache, neck pain 
or back pain were evaluated to determine if patient gender or health care provider gender 
influenced the number, type and dosage of medications received for their pain. The main 
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finding of this study showed that female patients tended to perceive more pain than their 
male counterparts.  Female patients also received more medications and stronger 
medications than males. 
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2.7 Summary 
 
This chapter presents a summary of the potential cellular and molecular 
mechanisms, historical background, review of relevant studies and the need for the 
current study.  It is apparent through the review of the literature that the connection 
between AMPK activation through metformin may inhibit the mTOR pathway, which 
may decrease pain.  No study to date has linked metformin treatment to decreased pain in 
a pre-diabetic population. 
In addition, this study opens up a new possible medication in relieving diabetic 
chronic pain and may have implications for other chronic pain conditions.  The review of 
the literature discusses the current studies related to the intracellular mechanisms of 
metformin, AMPK and mTOR as well as studies showing metformin’s pain reducing 
effect on animal models. The next chapter will discuss the methodology utilized for this 
study. 
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CHAPTER 3: METHODOLOGY 
 
 
3.1 Introduction 
 
The purpose of this chapter is focused on the research design, hypothesis, 
population of interest, subject selection, instrumentation and procedures used for this 
study. The goal for conducting this research was to analyze the pain scores, as measured 
by the SF-36 Health Survey of Bodily Pain Scores (SF-36 BPS), of pre-diabetic patients 
who were randomized to either the metformin group or the placebo group.  It was 
hypothesized that the metformin patients would have less pain (higher SF-36 BPS) than 
the placebo patients annually. 
This study used quantitative research methods. Quantitative research was 
descriptive based on specific inclusion and exclusion criteria which will be described in 
Section 3.3 Research Design. 
 
 
3.2 Primary Study 
 
The Diabetes Prevention Program (DPP) and Diabetes Prevention Program 
Outcomes Study (DPPOS) were conducted from 1996 to 2001 (DPP) and from 2002 to 
2008 (DPPOS) by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK) of the National Institutes of Health (NIH) (Diabetes Prevention Program 
Research Group, 1999 & 2000; Diabetes Prevention Program Research Group et al., 
2009; Fujimoto & Diabetes Prevention Program Research Group, 2000; Ratner & 
Diabetes Prevention Program Research Group, 2006; Rubin et al., 2002). The DPP 
recruited participants from over 27 clinical centers around the United States. Participants 
were randomized into a metformin group, placebo group or lifestyle intervention group.  
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The DPPOS was a follow up study to the DPP which occurred after a one year 
washout/bridge period (Diabetes Prevention Program Research Group et al., 2009). 
The DPP included 3,234 participants of which 1,082 were assigned to the placebo 
group, 1,073 were assigned to the metformin group and 1,079 were assigned to the 
lifestyle group (Knowler et al., 2002).  The demographics for the participants in the DPP 
are presented in Table 3.1.  The target population of this study was a pre-diabetic 
population, which was defined as fasting plasma glucose (FPG) of less than 126 mg/dl 
and a two-hour post-load plasma glucose of greater than 140 mg/dl but less than 200 
mg/dl.  The results of this study showed that lifestyle intervention and metformin 
treatment both reduced the incidence of pre-diabetic patients developing diabetes 
(Knowler et al., 2002). 
The DPPOS included 2,766 of the original DPP participants of which 932 were 
from the placebo group, 924 were from the metformin group and 910 were from the 
lifestyle group.  The demographics for the participants in the DPPOS are presented in 
Table 3.1.  The results showed that lifestyle intervention and metformin treatment 
prevented or delayed the onset of diabetes for 10 years (Diabetes Prevention Program 
Research Group, 2009). 
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Table 3.1 Demographic Data from the Diabetes Prevention Program and Diabetes 
Prevention Program Outcomes Study 
 
Demographic DPP Participants  
(N = 3234) 
DPPOS Participants  
(N = 2766) 
 
Gender 
Male  
Female 
 
 
1043 (32.3%) 
2191 (67.7%) 
 
 
888 (32.1%) 
1878 (67.9%) 
 
Race 
White 
African American  
Hispanic  
American Indian  
Asian 
 
 
1768 (54.7%) 
645 (19.9%) 
508 (15.7%) 
171 (5.3%) 
142 (4.4%) 
 
 
1506 (54.4%) 
559 (20.2%) 
424 (15.3%) 
153 (5.5%) 
124 (4.5%) 
 
Average Age (years) 
 
50.6 ± 10.7 
 
55.2 ± 10.3 
 
Average Weight (kg) 
 
94.2 ± 20.3 
 
95.6 ± 20.2 (Men) 
90.3 ± 21.0 (Women) 
 
Average BMI (kg/m
2
) 
 
34.0 ± 6.7 
 
31.1 ± 5.9 (Men) 
34.2 ± 7.2 (Women) 
Source: Knowler et al., 2002; Diabetes Prevention Program Research Group, 2009. 
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3.3 Research Design 
 
We conducted secondary data analyses of the Diabetes Prevention Program (DPP) 
and Diabetes Prevention Program Outcomes Study (DPPOS) using the measurements 
listed in Section 3.6. 
The eligibility criteria for the Primary Study were as follows (Diabetes Prevention 
Program Research Group, 1999): 
(1)  age ≥ 25 years; 
 
(2) body mass index (BMI)  ≥ 24 kg/m2 (≥ 22 kg/m2 among Asian 
Americans); 
(3) impaired glucose tolerance (IGT) defined as two-hour plasma glucose of 
140– 199 mg/dl based on 75-g oral glucose tolerance test); 
(4) elevated fasting plasma glucose (FPG) defined as < 126 mg/dl, except 
in the American Indian centers. 
Inclusion criteria for the present study were as follows: 
 
(1) eligibility criteria for the Diabetes Prevention Program. 
 
(2) SF-36 BPS, initial score and at least one annual score up until year four. 
 
(3) ≥ 80% compliance to either metformin or placebo (medication 
adherence was documented at annual visits by a medication adherence interview [See 
Appendix F]). 
Exclusion criteria were the following (Diabetes Prevention Program Research 
Group, 1999): 
(1) diabetes (FPG ≥ 126 mg/dl) at baseline (including ever using 
antidiabetic medication other than during pregnancy); 
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(2) cardiovascular disease (hospitalization for treatment of heart disease in 
past 6 months; New York Heart Association Functional Class > 2; left bundle branch 
block or third degree AV (atrioventricular) block; aortic stenosis; systolic blood pressure 
> 180 mmHg or diastolic blood pressure > 105 mmHg); 
(3) cancer requiring treatment in the past 5 years, unless the prognosis is 
considered good; 
(4) renal disease (creatinine ≥ l.4 mg/dl for men, or ≥ 1.3 mg/dl for women, 
or urine protein  ≥ 2+); 
(5) anemia (hematocrit < 36% in men or < 33% in women); 
 
(6) hepatitis (based on history or serum transaminase elevation); 
 
(7) other gastrointestinal disease (pancreatitis, inflammatory bowel disease); 
 
(8) recent or significant abdominal surgery; 
 
(9) pulmonary disease with dependence on oxygen or daily use of 
bronchodilators; 
(10) chronic infection (e.g., human immunodeficiency virus, active 
tuberculosis); 
(11) conditions or behaviors likely to affect conduct of the trial (unable to 
communicate with clinic staff; unwilling to accept treatment assignment by 
randomization; participation in another intervention research project that might interfere 
with DPP; weight loss of > 10% in past 6 months for any reason except postpartum 
weight loss; unable to walk 0.25 miles in 10 min); 
(12) pregnant, nursing, intend to become pregnant, unwilling to take 
contraception; 
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(13) major psychiatric disorder, such as schizophrenia; 
(14) excessive alcohol intake, either acute or chronic (average consumption of 
3 or more alcohol containing beverages daily; consumption of 7 or more alcoholic 
beverages within a 24 hour period in the past 12 months; clinical assessment of alcohol 
dependence based on two or more positive responses to the CAGE questionnaire); 
(15) current use of thiazide diuretics, β-blockers, niacin, 
glucocorticoids, selective serotonin re-uptake inhibitors, other prescription 
weight-loss medications; 
(16) thyroid disease; 
 
(17) other endocrine disorders (e.g., Cushing’s syndrome, acromegaly); 
 
(18) fasting plasma triglyceride > 600 mg/dl, despite treatment. 
 
 
 
3.4 Hypotheses 
 
Central Hypothesis.  Pre-diabetic patients at the end of metformin therapy, 
whether low dose (850 mg/day) or high dose (1,700 mg/day), will report less pain (as 
indicated by higher SF-36 BPS) than pre-diabetic patients in the placebo group annually 
(years 1-4). 
The following specific aims and hypotheses evaluated the central hypothesis: 
 
Primary Aim.  Evaluate the annual pain scores (SF-36 BPS) of pre-diabetic 
patients on metformin therapy and the placebo at each annual visit (years 1 – 4). 
Hypothesis 1A: Pre-diabetic patients on metformin (regardless of dose) 
will report less pain (measured by higher SF-36 BPS) compared to pre-diabetic 
patients in the placebo group at each annual visit (years 1 - 4). 
Secondary Aim 1.  Compare the pain scores among pre-diabetic patients on 
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placebo, low dose (850 mg/day) metformin therapy and high dose (1,700 mg/day) 
metformin therapy at each annual visit. 
Hypothesis 2A: The high dose (1,700 mg/day) metformin group will 
report the least pain (highest SF-36 BPS) compared to the placebo and low dose 
(850 mg/day) metformin groups at each annual visit. 
Secondary Aim 2.  Compare pain scores within each study group from baseline 
through year four of the study. 
Hypothesis 3A: Placebo patients will report greater pain at year one, two, 
three and four compared to baseline. 
Hypothesis 3B: Low dose (850 mg/day) metformin patients will exhibit 
no change in pain when comparing baseline, year one, year two, year three and 
year four pain scores. 
Hypothesis 3C: High dose (1,700 mg/day) metformin patients will report 
less pain when comparing year one, year two, year three and year four pain scores 
to baseline. 
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3.5 Population of Interest 
 
The target population of this study was an adult, pre-diabetic population which 
included individuals with a fasting plasma glucose (FPG) of less than 126 mg/dl and a 
two-hour post-load plasma glucose of greater than 140 mg/dl but less than 200 mg/dl. 
The specific eligibility and exclusion criteria are described in Section 3.2 Research 
Design.  Participants in the original DPP study were followed up quarterly for adverse 
symptoms including uncontrolled hyperglycemia.  If such was the case, a fasting blood 
glucose (FPG) was done in order to determine of the patient still met the study criteria. 
Additionally, the inclusion criteria for this current secondary data analyses included 
patients with an initial pain score (SF-36 BPS) and at least one annual pain score along 
with confirmed compliance of medication adherence at annual follow up. 
 
 
3.6 Measurements 
 
Measurements for this study included the following: 
 
(1) Bodily Pain - SF-36 BPS initially and at least one annual visit. 
 
The DPP/DPPOS utilized the SF-36 Health Survey, a 36-item short form 
health survey which measures health related quality of life.  It also contains a 
component measuring the intensity of and interference caused by bodily pain 
(Hawker, Milan, Kendzerska, & French, 2011).  The SF-36 Health Survey for 
Bodily Pain (SF-36 BPS) has been validated as an instrument for measuring pain 
in a diabetic population (Jacobsen et al., 1993).   Self-reported bodily pain 
intensity is rated from a score of 1 (none), 2 (very mild), 3 (mild), 4 (moderate), 5 
(severe) to 6 (very severe). A score is also obtained by reported pain interference 
with work rated from a score of 1 (not at all), 2 (a little bit), 3 (moderately), 4 
52  
(quite a bit) to 5 (extremely). The raw scale scores are then entered into an 
algorithm which results in a scale between 0 – 100 (http://www.sf-
36.org/demos/SF-36.html).  A score greater than or equal to 50 indicates normal 
or low bodily pain and a score less than 50 indicates higher bodily pain. Bodily 
pain is classified as higher as the SF-BPS score decreases (Hawker, Milan, 
Kendzerska, & French, 2011).  The population mean of the SF-36 BPS is 75.2 
with a standard deviation of 23.7 (Ware, 2000). Only 0.6% of the study 
population had the lowest possible SF-BPS score, indicating very severe and 
extremely limiting pain and 31.9% of the population reported the highest possible 
score which is no pain or limitations due to pain (Ware, 2000). The minimally 
important difference in the SP-36 BPS is three points (Ware et al., 2007).  The 
summary of measures concerning each component of the SF-36 is shown in 
Appendix D. 
(2) Metformin Therapy - dosage of metformin (850 mg/day or 1,700 mg/day) 
administered orally. 
(3) Medication compliance ≥ 80% (based on medication adherence interview 
[Appendix F]). 
(4)  Demographics - gender, age (< 40, 40-44, 45-49, 50-54, 55-59, 60-64, 
65+), race (Caucasian, African-American, Hispanic, Other) and BMI (<30, 30-35, 
35+).  Several studies have shown differences in pain based on gender, age, race 
and BMI (Green et al., 2003; ; Hitt et al., 2007; Krueger & Stone, 2008; Raftery et 
al., 1995). 
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3.7 Current Study Procedures 
 
A retrospective data analysis was conducted using the data obtained from the 
Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study 
(DPPOS).   The data used for this study included participants who were at least 80% 
compliant with the metformin and placebo treatment regimen throughout the study. 
Compliance was monitored at each annual visit through a patient interview.  The DPP 
lifestyle group was not included in this study as the effect of lifestyle intervention on pain 
scores was not the primary objective of interest of this study. There were 506 compliant 
patients in the metformin group (53 on 850 mg/day; 425 on 1,700 mg/day; 28 on mixed 
doses) and 550 compliant patients in the placebo group. The entire metformin group 
started on a dose of 850 mg per day and if this dose was tolerated (no gastrointestinal side 
effects), the dose was increased after four weeks to 850 mg twice per day, for a total of 
1,700 mg/day.  The placebo group was adjusted likewise in parallel to the metformin 
group. 
 
 
3.8 Institutional Review Board Approval 
 
The 27 clinical centers and the DPP Coordinating Center obtained institutional 
review board approvals to conduct the DPP/DPPOS.  Individuals provided written 
informed consent prior to participating in the study (Diabetes Prevention Program 
Research Group, 1999).   As no direct contact was made between the investigator and the 
patients for the current study, an exempt status review was requested and obtained from 
the Indiana University Institutional Review Board (see Appendix B for approval letters). 
In addition, approval to obtain and analyze the data was obtained from the National 
Institute of Diabetes and Digestive and Kidney Diseases (see Appendix C for approval 
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letters).  The de-identified dataset was free of personal patient information. 
 
 
3.9 Statistical Analysis 
 
Analyses were performed using SPSS version 22.0 (IBM Corp., Armonk NY). 
 
Descriptive statistics were used to show means, standard deviations, minimums and 
maximums. The research questions were examined using inferential statistics, 
specifically the Student’s independent t-tests, one-way analysis of variance (ANOVA) 
and repeated measures analysis of variance (ANOVA).  Because initial pain scores 
were evaluated before randomization into the placebo and metformin groups, 
independent t- tests were conducted comparing the initial pain scores and annual 
(years one through four) pain scores of the placebo and metformin (combined low 
dose [850 mg/day] and high dose [1,700 mg/day]) groups.  ANOVAs were conducted 
to examine differences among the placebo, low dose (850 mg/day) metformin and high 
dose (1,700 mg/day) metformin groups.  Repeated measures ANOVAs were 
conducted to compare the yearly change in pain scores of each study group.  Pearson’s 
chi-square analysis was performed to determine if confounding factors played a role in 
the results obtained in the study. 
Analysis of Hypothesis for the Primary Aim. The primary aim of this study 
was to evaluate the annual pain scores (SF-36 BPS) of pre-diabetic patients on metformin 
therapy and the placebo at each annual visit (years 1 – 4).  The initial and annual end pain 
scores (as measured by SF-36 BPS) for years one through four of pre-diabetic patients 
was analyzed.  Metformin therapy patients’ annual reported pain was hypothesized to be 
less than the placebo group (as indicated by an increase in SF-36 BPS).  Pain scores 
before initiation of metformin or placebo therapies was hypothesized to not be 
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significantly different. 
Analyses were performed to determine whether or not the initial and mean annual 
end reported pain scores among the metformin group (both low dose [850 mg/day] and 
high dose [1,700 mg/day] combined) and placebo group were significantly different. 
Independent t-tests were done to compare the initial and annual pain scores (years one 
through four) of both the placebo and combined metformin groups.   All analyses used p- 
values of less than 0.05 to determine if the means were statistically significant. 
The analysis of the initial pain scores before administration of metformin or 
placebo should show that the pain scores are not statistically significantly different (p- 
value > 0.05) to establish that metformin and placebo patients began with similar pain 
scores.  Conversely, a statistically significant difference in pain scores (p-value of less 
than 0.05) at each annual (following baseline) recording of pain scores after 
administration of metformin (low [850 mg/day] and high [1,700 mg/day] dose combined) 
or placebo should serve to confirm the hypothesis of the primary aim. 
Analysis of Hypotheses for Secondary Aim 1.  The secondary aim 1 of this 
study was to evaluate pain scores among pre-diabetic patients on placebo, low dose (850 
mg/day) metformin therapy and high dose (1,700 mg/day) metformin therapy at each 
annual visit. 
The mean annual pain scores, of years one through four, for each group (placebo, 
low dose [850 mg/day] metformin and high dose [1,700 mg/day] metformin) were 
analyzed.  It was hypothesized that pre-diabetic patients on a higher dose (1,700 mg/day) 
of metformin would report less pain (higher SF-36 BPS) than patients on the lower dose 
(850 mg/day) of metformin and placebo. 
To test this hypothesis, one-way analysis of variances (ANOVAs) were performed 
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comparing the initial pain scores and the average annual end pain scores of the placebo 
group compared to the higher dose (1,700 mg/day) of metformin and to the lower dose 
(850 mg/day) of metformin at a p-value of less than 0.05. The annual mean pain scores 
of the groups were then compared in order to determine if a difference would be observed 
among of the all groups. 
Analysis of Hypotheses for Secondary Aim 2.  The secondary aim 2 of this 
study was to compare the pain scores within each study group from baseline through year 
four. Baseline through year four pain scores within the placebo, low dose (850 mg/day) 
metformin and high dose (1,700 mg/day) metformin groups were further analyzed.  For 
the placebo group, it was hypothesized that the SF-36 BPS would decrease indicating 
more reported pain annually (years 1- 4) compared to the initial pain scores using p-value 
< 0.05. However, it was hypothesized that pain for years one through four would remain 
the same for the low dose (850 mg/day) metformin group and be less (increase in SF-36 
BPS) for the high dose (1,700 mg/day) metformin group when compared to the initial 
pain scores. 
Analyses using a repeated measures analysis of variances (ANOVAs) were 
performed comparing the average annual pain scores of baseline, year one, two, three and 
four of the placebo group. The same was done for the low dose (850 mg/day) metformin 
group and high dose (1,700 mg/day) metformin group.  These analyses were performed 
using an α = 0.05 significance level. These analyses were done to determine if there was 
a change in annual pain scores within each individual group. 
Analysis of Confounders. Gender, age, race and BMI (body mass index) were 
analyzed for possible confounding.  Raftery et al. (1995) noted that female patients in the 
emergency room indicated more pain and the health care providers also perceived that 
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female patients had more pain than their male counterparts. Krueger and Stone (2008) 
found that the average pain rating increased with age.  Hitt et al. (2007) showed that 
adults with a body max index (BMI) greater than 30 are more likely to report 
experiencing pain than normal or underweight counterparts. Green et al. (2003) found 
racial and ethnic differences in pain perception, assessment and treatment for subjects 
experiencing chronic, acute and cancer pain. Pearson’s Chi-square analyses were 
performed for each of these potential confounding variables and compared at an α = 0.05 
significance level.  Separate Pearson’s Chi-square analyses were performed for the 
metformin and placebo groups by gender, age, race and BMI categories. These analyses 
were performed to determine if gender, age, race or BMI category played a role in the 
results of this study. 
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3.10 Summary 
 
This chapter summarizes the secondary data analyses that were used in evaluating 
the central hypothesis and primary aims.  Eligibility, inclusion and exclusion criteria for 
the study were explained.  The detailed primary and secondary aims along with the 
specific hypotheses were discussed. The study procedures and types of statistical 
analyses used to test each hypothesis were described in this chapter. The next chapter 
will discuss the results in relation to the central hypothesis, primary and secondary aims. 
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CHAPTER 4: RESULTS 
 
 
4.1 Demographics 
 
Two-thousand fifty-seven adult, pre-diabetic patients were enrolled in the 
metformin and placebo arms of the Diabetes Prevention Program (DPP) and Diabetes 
Prevention Program Outcomes Study (DPPOS).  Of the original 2,057 patients, only 
1,056 patients met the criteria for the present study. 
Table 4.1 summarizes the demographic characteristics of the current study 
population. Of the study population, the majority was female (64.7%). The age 
distribution ranged from less than 40 to greater than 65 years of age. The largest age 
group was those between 45-49 years old (21.3%) followed by 50-54 year olds (19.9%). 
The remaining age group percentages are as follows: 55 and 59 years old (13.8%), 40 
and 44 years old (13.7%), 60 and 64 years old (11.2%), 65 years of age or older (10.3%) 
and less than 40 years old (9.8%). The race distributions were: 62% Caucasian, 18% 
African-American, 15.2% Hispanic and 4.8% classified as other. The majority of the 
population included in the analysis had a body mass index (BMI) greater than 30.  Nearly 
30.3% of the sample had a BMI between 30 and 35 and 36% had a BMI greater than 35. 
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Table 4.1  Demographic Characteristics of the Study Population 
 
Demographics Placebo Metformin 
Gender 
Male  
Female 
 
179 
371 
 
194 
312 
Age 
Less than 40 
40 – 44 
45 – 49 
50 – 54 
55 – 59 
60 – 64 
65 and over 
 
52 
72 
129 
93 
86 
65 
53 
 
51 
73 
96 
117 
60 
53 
56 
Race 
Caucasian  
African-American  
Hispanic 
Other 
 
349 
91 
81 
29 
 
306 
99 
79 
22 
BMI Group 
Less than 30 
30 to less than 35 
35+ 
 
183 
167 
200 
 
173 
153 
180 
 
 
 
4.2 Frequency of Initial Pain Scores 
 
Table 4.2 shows the descriptive statistics for the initial pain scores of all study 
patients. Figure 4.1 shows the frequency distribution of each initial pain score of all 
patients included in the study.  Tables 4.3 and 4.4 show the descriptive statistics of initial 
pain scores for the placebo group, low dose (850 mg/day) metformin group and high dose 
(1,700 mg/day) metformin group, respectively.  Figure 4.2 shows the frequency 
distribution of each initial pain score of the placebo patients. Figure 4.3 shows the 
frequency distribution of each initial pain score of the low dose (850 mg/day) metformin 
patients. Figure 4.4 shows the frequency distribution of each initial pain score of the high 
dose (1,700 mg/day) metformin patients. 
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Table 4.2 Descriptive Statistics of Initial Pain Scores of All Study Patients 
 
 
All Study Patients N = 1056 
Mean 79.1 
Median 84.0 
Mode 100.0 
Standard Deviation 18.8 
Variance 354.4 
 
 
 
 
Figure 4.1  Frequency Distribution of Initial Pain Scores of All Study Patients 
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Figure 4.2  Frequency Distribution of Initial Pain Scores of Placebo Patients 
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Figure 4.3  Frequency Distribution of Initial Pain Scores of Low Dose (850 
mg/day) Metformin Patients 
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Figure 4.4  Frequency Distribution of Initial Pain Scores of High Dose 
(1,700 mg/day) Metformin Patients 
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4.3 Confounders 
 
In order to minimize possible confounding in the study, statistical analyses were 
performed with the metformin and placebo groups. The analysis was conducted to 
determine whether specific variables (gender, age, race and body mass index (BMI)) may 
have influenced results of the study. Previous studies (referenced in Chapter 3) have 
shown differences in the pain experience based on gender, age, race and BMI. The 
findings pertaining to the confounders are summarized in Table 4.1. 
Gender.  There were 683 females and 373 males in the study.  In the placebo 
group, there were 371 females and 179 males. The metformin group consisted of 312 
females and 194 males.  A Pearson Chi-Square analysis was done and a p-value of 0.049 
was observed.  Because the p-value was extremely close to p-value < 0.05, the 
standardized residual was calculated. It was determined that no one variable dominated 
over the others.  The standard residuals for the placebo group were -1.1 for males and 0.8 
for female and for the metformin group, 1.1 for males and -0.8 for females (Table 4.3). 
Age.  There were seven age categories in the study (Table 4.1).  A Pearson Chi- 
Square analysis was done for the metformin and placebo groups versus the age 
categories.  A p-value of 0.069 was calculated indicating that metformin and placebo 
groups are independent of age (Table 4.3). 
Race.  There were four race categories in the study (Table 4.1).  A Pearson Chi- 
Square analysis was done for the metformin and placebo groups versus race categories. A 
p-value of 0.509 was calculated indicating that metformin and placebo groups are 
independent of race (Table 4.3). 
Body Max Index (BMI).  There were three categories of BMI groups in the study 
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Table 4.1).  A Pearson Chi-Square analysis was done for the metformin and placebo 
groups versus BMI groups.  A p-value of 0.945 was calculated indicating that metformin 
and placebo groups are independent of BMI groups (Table 4.3). 
 
 
Table 4.3 Pearson Chi-Square Analysis of Potential Confounding Variables of 
Gender, Age, Race and BMI of Metformin and Placebo Groups. 
 
 
Variable p – value 
 
Gender 
 
0.049* 
 
Age 
 
0.069 
 
Race 
 
0.509 
 
BMI 
 
0.945 
*Standard residuals: Placebo group = -1.1 for males and 
0.8 for female; Metformin group, 1.1 for males and -0.8 for females. 
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4.4 Initial Pain Scores and Annual End Pain Scores of Metformin or 
Placebo Treatment 
 
Analysis of Initial Pain Scores.  Initial pain scores using the SF-36 BPS were 
taken upon eligibility screening for the original DPP study (Table 4.4). This screening 
was performed prior to randomization into the metformin or placebo groups. Because of 
this, an independent Student’s t-test was done as part of the analyses along with a one- 
way analysis of variance (ANOVA).  Using the independent Student’s t-test, the initial 
pain scores of the metformin and placebo groups were analyzed for statistical 
significance at p-value < 0.05. There was no statistically significant difference in the 
placebo group’s baseline pain scores (M = 78.2, SD = 19.4) and metformin group’s 
baseline pain scores [(M = 80.0, SD = 18.1); t(1054)= 1.603, p = 0.109; Table 4.5]. 
 
 
Table 4.4  Initial Pain Scores for the Placebo and Metformin Groups 
 
 
 
Group 
 
N 
 
Mean 
 
SD 
 
SEM 
 
Placebo 
 
550 
 
78.2 
 
19.4 
 
0.83 
 
Metformin 
850 mg/day 
1700 mg/day 
 
506 
53 
425 
 
80.0 
78.5 
80.5 
 
18.1 
18.3 
18.2 
 
0.807 
2.51 
0.88 
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Table 4.5 Independent T-Tests of Initial and Annual Pain Scores for the Placebo 
and Combined Metformin Groups 
 
  Initial Year 1 Year 2 Year 3 Year 4 
 
Levene’s Test for 
Equality of 
Variances 
 
F 
 
p 
 
3.55 
 
0.060 
 
1.05 
 
0.306 
 
7.72 
 
0.006 
 
3.14 
 
0.077 
 
1.70 
 
0.192 
 
t-test for Equality 
of Means 
 
t  
 
df  
 
p 
 
Mean 
Difference 
 
SE 
Difference 
 
1.60 
 
1054 
 
0.109 
 
1.86 
 
 
1.16 
 
1.41 
 
1051 
 
0.158 
 
1.71 
 
 
1.21 
 
2.65 
 
1049 
 
0.008* 
 
3.36 
 
 
1.27 
 
0.984 
 
1035 
 
0.325 
 
1.22 
 
 
1.24 
 
1.03 
 
645 
 
0.305 
 
1.66 
 
 
1.62 
 
95% CI of the 
Difference 
 
Lower  
 
Upper 
 
-0.416 
 
4.13 
 
-0.666 
 
4.09 
 
0.868 
 
5.86 
 
-1.21 
 
3.66 
 
-1.52 
 
4.84 
*significant at p < 0.05 
 
 
A one-way analysis of variance (ANOVA) was performed to examine whether 
initial pain scores (using the SF-36 BPS) among the placebo, low dose (850 mg/day) 
metformin and high dose (1,700 mg/day) metformin groups were different.  An alpha 
level of 0.05 was used for all analyses. 
The test for homogeneity of variance was not significant [Levene F(2, 1025) = 
1.70, p = 0.18] indicating that this assumption underlying the application of ANOVA was 
met. The one-way ANOVA of the initial pain scores revealed no statistically significant 
difference in the initial pain scores of the placebo, low dose (850 mg/day) metformin and 
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high dose (1,700 mg/day) metformin groups [F(2, 1025) = 1.95, p = 0.14]  (Table 4.6). 
 
Table 4.6  Analysis of Variance Summary Table of Initial Pain Scores for the 
Placebo, Low Dose (850 mg/day) Metformin and High Dose (1700 mg/day) 
Metformin Groups 
 
  
Sum of 
Squares 
 
 
df 
 
Mean Square 
 
 
F 
 
 
p - value 
 
Between 
groups 
 
1385.935 
 
2 
 
692.967 
 
1.95 
 
0.143 
2 = 0.01 
 
Within 
groups 
 
364180.610 
 
1025 
 
355.298 
  
 
Total 
 
365566.545 
 
1027 
   
 
 
 
Analysis of Annual End Pain Scores.  Pain scores were recorded in the parent 
study using the SF-36 BPS at each annual visit. These average pain scores are reported in 
Table 4.7. All patients included in the study had at least one annual follow up during the 
course of the study, with some patients having follow-up data for up to six years.  In 
conducting the analyses it was determined that follow up years five and six had too small 
of a sample size (Metformin n = 115; Placebo n = 114 and Metformin n = 3, Placebo n = 
5, respectively), to include in the end analyses, therefore only years one through four 
were used as part of the analyses. 
The mean pain scores for the placebo, low dose (850 mg/day) metformin and high 
dose (1,700 mg/day) metformin groups were analyzed at years one, two, three and four. 
Independent t-tests between placebo and the combined metformin groups were performed 
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to compare pain scores for each year.  In addition, one-way ANOVAs were done 
comparing the individual group mean pain scores for each year. An alpha level of 0.05 
was used for all analyses. 
 
Table 4.7   Descriptives of Annual Average End Pain Scores for the Placebo, Low 
Dose (850 mg/day) Metformin and High Dose (1,700 mg/day) Metformin Groups 
 
     95% CI 
Group N Mean SD SEM Lower Upper 
 
Year One 
Placebo  
850 mg 
1700 mg 
 
 
550 
53 
423 
 
 
77.7 
71.8 
80.7 
 
 
20.3 
21.7 
18.4 
 
 
0.86 
2.99 
0.89 
 
 
76.0 
65.8 
78.9 
 
 
79.4 
77.8 
82.5 
 
Year Two 
Placebo  
850 mg 
1700 mg 
 
 
549 
52 
423 
 
 
75.2 
68.6 
80.1 
 
 
21.8 
20.6 
18.9 
 
 
0.93 
2.86 
0.92 
 
 
73.4 
62.8 
78.3 
 
 
77.0 
74.3 
81.9 
 
Year Three 
Placebo  
850 mg 
1700 mg 
 
 
540 
51 
418 
 
 
76.2 
70.5 
78.4 
 
 
20.8 
20.8 
18.8 
 
 
0.89 
2.91 
0.92 
 
 
74.4 
64.7 
76.6 
 
 
78.0 
76.4 
80.2 
 
Year Four 
Placebo  
850 mg 
1700 mg 
 
 
339 
27 
263 
 
 
74.8 
71.5 
76.9 
 
 
21.5 
20.9 
19.5 
 
 
1.17 
4.03 
1.20 
 
 
72.5 
63.2 
74.6 
 
 
77.1 
79.8 
79.3 
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Year One Pain Scores.  For year one, the independent t-test showed that there was 
not a significant difference in year one placebo pain scores (M = 77.7, SD = 20.3) and 
year one combined metformin group pain scores [(M = 79.4, SD = 18.9); t(1051)= 1.412, 
p = 0.158; Table 4.5]. For the year one ANOVA, the test for homogeneity of variance 
was not significant [Levene F(2, 1023) = 2.74, p = 0.065] indicating that this assumption 
underlying the application of ANOVA was met.  The one-way ANOVA of year one pain 
scores (Table 4.8) revealed significance among the three groups [F(2, 1023) = 6.24, p = 
0.002].  Post hoc comparisons using Tukey procedures were performed to determine 
which pairs of the three group means differed. These results are shown in Table 4.9 and 
indicate two differences.  The high dose (1,700 mg/day) metformin group (M = 80.7) 
reported less pain (higher SF-36 BPS) than the placebo group (M = 77.7) with a p-value 
of 0.047.  The high dose (1,700 mg/day) metformin group (M = 80.7) also reported less 
pain than the low dose (850 mg/day) metformin group (M = 71.8) with a p-value of 
0.005.  The effect size, eta squared (2), for this finding was 0.01 (ω2 of 0.01).  The 
Cohen’s d for year one placebo and high dose (1,700 mg/day) metformin groups was 
0.15 (Cohen’s U3 of 56%) and the Cohen’s d for year one low dose (850 mg/day) 
metformin and high dose (1,700 mg/day) metformin groups was 0.44 (Cohen’s U3 of 
67%). 
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Table 4.8  Analysis of Variance Summary Table for Pain Scores for the Placebo, 
Low Dose (850 mg/day) and High Dose (1700 mg/day) Metformin Groups in Year 
One 
 
  
Sum of 
Squares 
 
 
df 
 
Mean Square 
 
 
F 
 
 
p - value 
 
Between 
groups 
 
4784.937 
 
2 
 
2394.469 
 
6.237 
 
0.002* 
2 = 0.01 
 
Within 
groups 
 
392422.837 
 
1023 
 
383.6 
  
 
Total 
 
397207.774 
 
1025 
   
*significant at p < 0.05 
 
 
 
Table 4.9 Tukey’s HSD Test For Year One Pain Scores of Placebo, Low Dose 
(850 mg/day) and High Dose (1,700 mg/day) Metformin Groups 
 
     95% CI 
Group 1 Group 2 Mean 
Difference 
SEM P Lower Upper 
 
Placebo 
 
850 mg 
 
5.92 
 
2.82 
 
0.09 
 
-0.69 
 
12.5 
 
Placebo 
 
1700 mg 
 
3.01 
 
1.27 
 
0.047* 
dCohen   = 0.15 
 
-5.98 
 
-0.03 
 
850 mg 
 
1700 mg 
 
8.92 
 
2.85 
 
0.005* 
dCohen   = 0.44 
 
-15.6 
 
-2.23 
*significant at p < 0.05 
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Year Two Pain Scores.  For year two, the independent t-test showed a significant 
difference in year two placebo pain scores (M = 75.2, SD = 21.8) and year two combined 
metformin group pain scores [(M = 78.6, SD = 19.4); t(1050)= 2.645, p = 0.008; Table 
4.5].  For the year two ANOVA, the test for homogeneity of variance was significant 
[Levene F(2, 1021) = 5.74, p = 0.003] indicating that this assumption underlying the 
application of ANOVA was not met (Table 4.10).  In instances where heterogeneity of 
variance is observed, the Welch and Brown-Forsythe tests are recommended as 
alternatives (Stevens, 1999; Tomarken & Serlin, 1986).  Therefore, the Welch [F(2, 
141.4) = 11.7, p = 0.000] and Brown-Forsythe tests [F(2, 205.8) = 11.4, p = 0.000] both 
revealed a significance among the three groups (Table 4.11). Post hoc comparisons using 
Tamhane procedures were performed to determine which pairs of the three group means 
differed. These results are given in Table 4.12 and indicate two statistically significant 
differences.  The high dose (1,700 mg/day) metformin group (M = 80.1) had less pain 
(higher SF-36 BPS) than the placebo group (M = 75.2) with a p-value of 0.001. The high 
dose (1,700 mg/day) metformin group (M = 80.1) also had less pain than the low dose 
(850 mg/day) metformin group (M = 68.6) with a p-value of 0.001. The Cohen’s d for 
year two placebo and high dose (1,700 mg/day) metformin groups was 0.24 (Cohen’s U3 
of 59.5%). Cohen’s d for year two low dose (850 mg/day) metformin and high dose 
(1,700 mg/day) metformin groups was 0.58 (Cohen’s U3 of 72%). 
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Table 4.10 Levene’s Test of Homogeneity of Variances for Year Two Pain Scores 
of Placebo, Low Dose (850 mg/day) and High Dose (1700 mg/day) Metformin 
Groups 
 
 
Levene Statistic 
 
df1 
 
df2 
 
p-value 
 
5.74 
 
2 
 
1021 
 
0.003* 
*significant at p < 0.05 
 
 
Table 4.11  Robust Tests of Equality of Means for Year Two Pain Scores of 
Placebo, Low Dose (850 mg/day) and High Dose (1700 mg/day) Metformin Groups 
 
 Statistic df1 df2 p - value 
 
Welch 
 
11.7 
 
2 
 
141.4 
 
0.000* 
 
Brown-Forsythe 
 
11.4 
 
2 
 
205.8 
 
0.000* 
*significant at p < 0.05; 2 =  0.02 
 
Table 4.12 Tamhane’s Test for Year Two for Placebo, Low Dose (850 mg/day) 
Metformin and High Dose (1700 mg/day) Metformin Groups 
 
     95% CI 
Group 1 Group 2 Mean 
Difference 
SEM P Lower Upper 
 
Placebo 
 
850 mg 
 
6.64 
 
3.00 
 
0.089 
 
-0.72 
 
14.0 
 
Placebo 
 
1700 mg 
 
4.86 
 
1.31 
 
0.001* 
dCohen   = 0.24 
 
-7.99 
 
-1.74 
 
850 mg 
 
1700 mg 
 
11.5 
 
3.00 
 
0.001* 
dCohen   = 0.58 
 
-18.9 
 
-4.15 
*significant at p < 0.05 
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Year Three Pain Scores. For year three, the independent t-test showed that there 
was not a significant difference in year three placebo group pain scores (M = 76.2, SD = 
20.8) and year three combined metformin group pain scores [(M = 77.4, SD = 19.0); 
t(1035) = 0.984, p = 0.325; Table 4.5]. For the year three ANOVA analysis, the test for 
homogeneity of variance was not significant [Levene F(2, 1006) = 2.00, p = 0.136] 
indicating that this assumption underlying the application of ANOVA was met. The one- 
way ANOVA of year three pain scores (Table 4.13) revealed a significance among the 
three groups [F(2, 1006) = 4.12, p = 0.016]. Post hoc comparisons using Tukey 
procedures were used to determine which pairs of the three group means differed. These 
results are presented in Table 4.14 and indicate that the high dose (1,700 mg/day) 
metformin group (M = 78.4) reported less pain (p = 0.021) than the low dose (850 
mg/day) metformin group (M = 70.5). The effect size for this finding was small (2 = 
0.01; ω2 = 0.006). The Cohen’s d for year three low dose (850 mg/day) metformin and 
high dose (1,700 mg/day) metformin groups was 0.40 (Cohen’s U3 of 65.5%). 
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Table 4.13 Analysis of Variance Summary Table of Pain Scores for the Placebo, 
Low Dose (850 mg/day) and High Dose (1700 mg/day) Metformin Groups in Year 
Three 
 
  
Sum of Squares 
 
df 
 
Mean Square 
 
F 
 
p - value 
 
Between 
groups 
 
3300.787 
 
2 
 
1650.4 
 
4.12 
 
0.016* 
2 = 0.01 
 
Within 
groups 
 
402859.907 
 
1006 
 
400.5 
  
 
Total 
 
406160.694 
 
1008 
   
*significant at p < 0.05 
 
 
Table 4.14  Tukey’s HSD of Year Three Pain Scores for the Placebo, Low Dose 
(850 mg/day) and High Dose (1,700 mg/day) Metformin Groups 
 
     95% CI 
Group 1 Group 2 Mean 
Difference 
SEM P Lower Upper 
 
Placebo 
 
850 mg 
 
5.69 
 
2.93 
 
0.127 
 
-1.19 
 
12.6 
 
Placebo 
 
1700 mg 
 
2.21 
 
1.30 
 
0.207 
 
-5.27 
 
0.847 
 
850 mg 
 
1700 mg 
 
7.91 
 
2.97 
 
0.021* 
dCohen   = 0.40 
 
-14.9 
 
-0.94 
*significant at p < 0.05 
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Year Four Pain Scores. For year four, the independent t-test showed that there 
was not a significant difference between year four placebo group pain scores (M = 74.8, 
SD = 21.5) and year four combined metformin group pain scores [(M = 76.5, SD = 19.5); 
t(645) = 1.027, p = 0.305; Table 4.5].  For the year four ANOVA, the test for 
homogeneity of variance was not significant [Levene F(2, 626) = 1.34, p = 0.263] 
indicating that this assumption underlying the application of ANOVA was met. The one- 
way ANOVA of the initial pain scores (Table 4.15) revealed no significance among the 
three groups [F(2, 626) = 1.32, p = 0.27] indicating that there was no difference in year 
four pain scores of the placebo, low dose (850 mg/day) metformin and high dose (1,700 
mg/day) metformin groups. 
 
Table 4.15 Analysis of Variance Summary Table for Pain Scores for the Placebo, 
Low Dose (850 mg/day) and High Dose (1,700 mg/day) Metformin Groups in 
Year Four 
 
  
Sum of 
Squares 
 
 
df 
 
Mean Square 
 
 
F 
 
 
p - value 
 
Between 
groups 
 
1120.329 
 
2 
 
560.164 
 
1.318 
 
0.269 
 
Within 
groups 
 
266145.137 
 
626 
 
425.152 
  
 
Total 
 
267265.466 
 
628 
   
78  
4.5 Annual Pain Scores for Placebo, Low Dose and High Dose 
Metformin Therapy 
 
Placebo Patients.  A repeated measures one-way analysis of variance (ANOVA) 
was used to examine pain scores (using the SF-36 BPS) of placebo patients at baseline, 
year one, two, three and four.  Only the placebo patients that had pain scores for baseline 
and years one through four were analyzed. The descriptives are shown in Table 4.16. An 
alpha level of 0.05 was used for all analyses. 
Mauchly's Test of Sphericity indicated that the assumption of sphericity had been 
violated [χ2(9) = 24.4, p = 0.004; Table 4.17]. The Greenhouse-Geisser estimate of 
sphericity (ε) is 0.966.  Therefore, a repeated measures ANOVA with a Huynh-Feldt 
correction was performed. Results of the analysis revealed that the mean pain scores 
differed statistically between time points [F(3.916, 1311.875) = 4.264, p = 0.002; Table 
4.18].  Post hoc tests using the Bonferroni correction further revealed that pain scores 
differed between initial pain scores (M = 77.7, SD = 19.7) and year two pain scores (M = 
73.7, SD = 22.8) at p = 0.012 (Table 4.19).  Reported pain scores also differed between 
year one (M = 77.4, SD = 21.3) and year two (M = 73.7, SD = 22.8) at p = 0.021 (Table 
4.19).  2 was 0.013 which indicates a small effect. 
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Table 4.16  Pain Score Values of the Placebo Patients for Baseline Through Year 
Four 
 
     95% CI 
Placebo N Mean SD SEM Lower Upper 
 
Baseline 
 
336 
 
77.7 
 
19.7 
 
1.08 
 
75.6 
 
79.8 
 
Year One 
 
336 
 
77.4 
 
21.3 
 
1.16 
 
75.2 
 
79.7 
 
Year Two 
 
336 
 
73.7 
 
22.8 
 
1.24 
 
71.3 
 
76.1 
 
Year Three 
 
336 
 
75.9 
 
21.2 
 
1.15 
 
73.6 
 
78.2 
 
Year Four 
 
336 
 
74.7 
 
21.5 
 
1.17 
 
72.4 
 
77.0 
 
 
 
Table 4.17 Mauchly’s Test of Sphericity for Placebo Group at Baseline Through 
Year Four 
 
 
Mauchly’s W 
 
Approx χ2 
 
df 
 
p-value 
Greenhouse- 
Geisser (ε) 
 
0.929 
 
24.4 
 
9 
 
0.004* 
 
0.966 
*significant at p < 0.05 
 
 
Table 4.18 Huynh-Feldt Correction for Placebo Group at Baseline Through Year 
Four 
 
Type III SS df Mean Square F p – value Partial 
2 
Power 
 
3999.877 
 
3.916 
 
1021.408 
 
4.264 
 
0.002* 
 
0.013 
 
0.925 
*significant at p < 0.05 
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Table 4.19 Post Hoc Bonferroni Correction for Placebo Group at Baseline 
Through Year Four 
 
     95% CI 
Group 1 Group 2 Mean 
Difference 
SEM P Lower Upper 
 
Baseline 
 
Year 1 
Year 2 
Year 3 
Year 4 
 
0.244 
3.99 
1.79 
3.01 
 
1.11 
1.22 
1.21 
1.15 
 
1.00 
0.012* 
1.00 
0.092 
 
-2.92 
0.551 
-1.62 
-0.235 
 
3.41 
7.42 
5.20 
6.26 
 
Year 1 
 
Year 2 
Year 3 
Year 4 
 
3.74 
1.55 
2.77 
 
1.21 
1.20 
1.23 
 
0.021* 
1.00 
0.245 
 
0.326 
-1.86 
-0.693 
 
7.16 
4.95 
6.23 
 
Year 2 
 
Year 3 
Year 4 
 
2.20 
0.973 
 
1.22 
1.22 
 
0.725 
1.00 
 
-5.64 
-4.41 
 
1.25 
2.46 
 
Year 3 
 
Year 4 
 
1.22 
 
1.04 
 
1.00 
 
-1.72 
 
4.16 
 
 
 
 
Low Dose (850 mg/day) Metformin Patients.  A repeated measures one-way 
analysis of variance (ANOVA) was used to examine pain scores (using the SF-36 BPS) 
of low dose (850 mg/day) metformin patients at baseline, year one, two, three and four. 
The descriptives are shown in Table 4.20. An alpha level of 0.05 was used for all 
analyses. 
Mauchly's Test of Sphericity indicated that the assumption of sphericity had not 
been violated [χ2(9) = 10.2, p = 0.333; Table 4.21] suggesting that the assumption of 
sphericity underlying the application of ANOVA was met.  The repeated measures 
ANOVA revealed no statistically significant differences among all of the analyzed years 
for the low dose metformin group [F(4, 104) = 1.55, p = 0.195] (Table 4.22). 
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Table 4.20 Descriptives of Low Dose (850 mg/day) Metformin Patients for 
Baseline Through Year Four 
 
     95% CI 
Low Dose Metformin N Mean SD SEM Lower Upper 
 
Baseline 
 
27 
 
77.0 
 
21.7 
 
4.17 
 
68.5 
 
85.6 
 
Year One 
 
27 
 
67.2 
 
21.9 
 
4.21 
 
58.6 
 
75.9 
 
Year Two 
 
27 
 
66.6 
 
18.8 
 
3.61 
 
59.2 
 
74.0 
 
Year Three 
 
27 
 
71.7 
 
22.6 
 
4.35 
 
62.8 
 
80.7 
 
Year Four 
 
27 
 
71.5 
 
20.9 
 
4.03 
 
63.2 
 
79.8 
 
 
Table 4.21 Mauchly’s Test of Sphericity for Low Dose (850 mg/day) Metformin 
Baseline Through Year Four 
 
 
Mauchly’s W 
 
Approx χ2 
 
df 
 
p-value 
 
0.658 
 
10.2 
 
9 
 
0.333 
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Table 4.22 Repeated Measures Analysis of Variance for Low Dose (850 mg/day) 
Metformin Baseline Through Year Four 
 
 Type III Sum 
of Squares 
df Mean 
Square 
F p Partial 
2 
Power 
 
Sphericity 
Assumed 
 
Error 
 
1909.852 
 
 
32128.548 
 
4 
 
 
104 
 
477.463 
 
1.55 
 
0.195 
 
0.056 
 
0.463 
 
 
 
 
High Dose (1,700 mg/day) Metformin Patients.  A repeated measures one-way 
analysis of variance (ANOVA) was used to examine pain scores (using the SF-36 BPS) 
of high dose (1,700 mg/day) metformin patients at baseline, year one, two, three and four. 
The descriptives are shown in Table 4.23. An alpha level of 0.05 was used for all 
analyses. 
Mauchly's Test of Sphericity indicated that the assumption of sphericity had not 
been violated [ χ2(9) = 13.2, p = 0.154; Table 4.24] indicating that the assumption of 
sphericity underlying the application of ANOVA was met.  The repeated measures 
ANOVA revealed no significance among the five time points for the high dose (1,700 
mg/day) metformin group [F(4, 1032) = 1.03, p = 0.088] indicating no statistical 
difference in baseline, year one, year two, year three and year four pain scores in the high 
dose metformin group (Table 4.25). 
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Table 4.23  Descriptives of High Dose (1,700 mg/day) Metformin Patients for 
Baseline Through Year Four 
 
     95% CI 
High Dose Metformin N Mean SD SEM Lower Upper 
 
Baseline 
 
259 
 
79.7 
 
18.8 
 
1.17 
 
77.4 
 
82.0 
 
Year One 
 
259 
 
79.8 
 
18.9 
 
1.17 
 
77.5 
 
82.1 
 
Year Two 
 
259 
 
79.0 
 
19.7 
 
1.22 
 
76.6 
 
81.4 
 
Year Three 
 
259 
 
78.3 
 
18.8 
 
1.17 
 
76.0 
 
80.6 
 
Year Four 
 
259 
 
76.7 
 
19.4 
 
1.21 
 
74.3 
 
79.1 
 
Table 4.24 Mauchly’s Test of Sphericity for High Dose (1,700 mg/day) Metformin 
Baseline Through Year Four 
 
 
Mauchly’s W 
 
Approx χ2 
 
df 
 
p-value 
 
0.950 
 
13.2 
 
9 
 
0.154 
 
 
Table 4.25 Repeated Measures Analysis of Variance for High Dose (1,700 
mg/day) Metformin Baseline Through Year Four 
 
 Type III Sum 
of Squares 
df Mean 
Square 
F p Partial 
2 
Power 
 
Sphericity 
Assumed 
 
Error 
 
1680.113 
 
 
213795.887 
 
4 
 
 
1032 
 
420.028 
 
2.03 
 
0.088 
 
0.008 
 
0.609 
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4.6 Summary 
 
The primary aim of this study was to assess whether pre-diabetic patients on 
metformin therapy reported lower pain scores than pre-diabetic patients given a placebo. 
In addition to this primary aim, the dosage of metformin was also evaluated in order to 
determine if the dosage correlated to lower reported pain.   A graph summarizing all 
average initial and annual pain scores is shown in Figure 4.5. 
 
Figure 4.5  Average Annual Pain Scores For Placebo, Low Dose (850 mg/day) and 
High Dose (1,700 mg/day) Metformin Groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to test the hypotheses, Student’s independent t-tests, one-way ANOVAs 
and repeated measures ANOVAs were completed.  The confounding variables of gender, 
age, race and BMI were also evaluated in order to determine if these variables played a 
role in the observed outcomes.  The results of these statistical analyses were presented in 
this chapter and these results will be discussed in the next chapter. 
Annual Pain Scores 
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CHAPTER 5: DISCUSSION 
 
 
Although metformin therapy has been used for many years in the diabetic 
population to help control blood glucose levels, the authors are not aware of any studies 
that have investigated the possible correlation between metformin use and pre-diabetic 
patients’ pain scores.  Previous research has shown that metformin decreases chronic pain 
in animal models and in human populations experiencing certain chronic pain conditions. 
Based on the intracellular mechanism of metformin, coupled with its greater tolerability, 
metformin is a medication that warrants further research pertaining to its potential pain 
relieving properties. 
The overall purpose of the study was to evaluate the association of metformin 
therapy and pain scores in a pre-diabetic population. This association was evaluated by 
comparing the SF-36 bodily pain scores of a pre-diabetic population undergoing 
metformin therapy versus a pre-diabetic population taking a placebo. Further evaluation 
of this association was conducted by comparing the SF-36 bodily pain scores of the pre- 
diabetic population annually.  It was hypothesized that the metformin patients would 
report less pain than the placebo patients annually. This chapter summarizes the findings 
from the study, presents conclusions drawn from these findings and proposes next steps 
for future research. 
87  
5.1 Analysis of the Primary Aim 
 
Hypothesis #1A: Pre-diabetic patients on metformin (regardless of dose) will 
have less pain (measured by higher SF-36 BPS) compared to pre-diabetic 
patients on placebo at each annual visit (years 1 - 4). 
Year two (Table 4.5) showed a significant difference [t(1050)= 2.645, p = 0.008] 
between placebo pain scores (M = 75.2, SD = 21.8) and combined metformin pain scores 
(M = 78.6, SD = 19.4).  However, all other years did not indicate statistical differences. 
The initial pain scores between the two groups were not statistically significant [t(1054)= 
1.603, p = 0.109].  The results of the analyses show that pre-diabetic patients on 
metformin had less pain compared to pre-diabetic patients on placebo only at year two. 
Possible explanations for this result will be discussed later in this chapter.  This study 
does not totally support previous animal and human studies which have found a reduction 
in pain through the use of metformin. 
Metformin, through the activation of AMPK, has been shown to decrease chronic 
pain in animal models.  A complete reversal of pain in mice on metformin therapy was 
found by Melemedjian et al. (2011). Russe et al. (2013) showed anti-nociceptive effects 
in mice models on metformin.  Mao-Ying et al. (2014) used metformin to reduce pain in 
mice with neuropathic pain induced by chemotherapy. This association between 
metformin treatment and pain reduction is not only limited to animal models but has also 
been reported in a human population. A decrease in lumbar radiculopathic pain in 
humans on metformin therapy was shown in a study by Taylor et al. (2013).   In addition, 
a single case observation of a patient with Decrum’s disease, which results in painful 
lipomas, showed a decrease in pain on metformin therapy (Labuzek et al., 2012; Labuzek 
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et al., 2013). 
To the author’s knowledge, the present study appears to be the first to explore 
metformin use for the reduction of chronic pain in a pre-diabetic population. This study 
indicated that metformin therapy is correlated to less reported pain in this population in 
year two.  The chronic pain in this population, can manifest itself nociceptively 
(primarily by skeletal muscle pain) but more commonly as painful diabetic neuropathy 
(Lieberman et al., 2014; Papanas et al., 2011).   However, it should be noted that both 
nociceptive pain and diabetic neuropathic pain have similar mechanisms involving 
activation of mTOR which is important in the mechanism through which metformin 
relieves pain (Chakravarty & Sen, 2010). 
The hypothesis of pre-diabetic patients on metformin therapy having less pain 
than pre-diabetic patients on placebo, however, was only confirmed in year two of this 
study. There was no difference found between the placebo and metformin groups in 
years one, three and four.   This finding could be the result of combining both high dose 
(1,700 mg/day) and low dose (850 mg/day) metformin groups. The 850 mg/day dose of 
metformin may be too low to make a difference in pain thus affecting the results.  In 
addition, the 1,700 mg/day high dose is not the recommended maintenance dose of 
metformin which is 2,000 mg/day.  These possible affects is addressed in the analysis of 
secondary aim 1. 
89  
5.2 Analysis of Secondary Aim 1 
 
Hypothesis #2A: The high dose metformin group (1,700 mg/day) will have the 
least pain (highest SF-36 BPS) compared to placebo and low dose (850 mg/day) 
metformin groups at each annual visit. 
The annual pain scores for each year were compared among the placebo, low dose 
(850 mg/day) metformin and high dose (1,700 mg/day) metformin groups (Table 4.7) 
separately.  The initial pain scores of all three groups were not statistically different [F(2, 
1025) = 1.95, p = 0.14; Table 4.6]. This is what was hypothesized as it was expected that 
there would be no differences in pain scores prior to administrating either treatment or 
placebo therapy. 
Year one pain scores exhibited a significant difference among the three groups 
[F(2, 1023) = 6.24, p = 0.002; Table 4.8]. Post hoc analyses revealed two significant 
differences (Table 4.9).  The high dose (1,700 mg/day) metformin group (M = 80.7) had 
less pain (higher SF-36 BPS) than the placebo group (M = 77.7) with a p-value of 0.047. 
The high dose (1,700 mg/day) metformin group (M = 80.7) also had less pain than the 
low dose (850 mg/day) metformin group (M = 71.8) with a p-value of 0.005. These 
results support the hypothesis that the high dose metformin group had the least pain 
compared to the placebo and low dose metformin groups. This finding was replicated in 
the year two pain score analysis. 
The results of analysis of the year three pain scores differed slightly from those of 
years one and two and did not entirely support the hypothesis.  While year three pain 
scores for the three groups were statistically significant [F(2, 1006) = 4.12, p = 0.016; 
Table 4.13], Tukey post hoc analyses determined that the high dose metformin group (M 
= 78.4) had less pain than the low dose metformin group (M = 70.5) with a p-value of 
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0.021.  However, the high dose metformin group was not statistically significantly 
different from the placebo group (M = 76.2; p = 0.207).  It was hypothesized that the 
high dose metformin group should have less pain than both the low dose metformin and 
placebo groups.  The later was not the case. 
Analysis of year four pain scores revealed no significance among all three 
groups [F(2, 626) = 1.32, p = 0.27; Table 4.15]. This result does not support the 
hypothesis of secondary aim 1.  Because of this result, a post hoc power analysis was 
done (Table 5.1) indicating very low power across all group comparisons.  The 
comparison between the placebo and low dose metformin groups had a post hoc power 
of 12.1%; the placebo and high dose metformin groups had a post hoc power of 24%; 
and the low dose metformin and high dose metformin groups had a post hoc power of 
25%. These findings suggest that despite the large overall sample size for this study, 
the reduced sample size for the annual analyses may have played a role in the non-
significant results. 
Table 5.1 Post Hoc Power Analyses for Year Four (Placebo N = 339; 850 mg/day N 
= 27; 1,700 mg/day N = 263) 
 
 
  Post 
Group 1 Group 2 hoc Power 
 
Placebo 
 
850 mg 
 
12.1% 
 
Placebo 
 
1700 mg 
 
24% 
 
850 mg 
 
1700 mg 
 
25% 
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To summarize, although it was hypothesized that the high dose metformin group 
would report less pain than the placebo and low dose metformin groups at each annual 
visit, a significant difference among high dose metformin, low dose metformin and 
placebo was only seen in years one and two .  In year three, a statistical significance was 
found only between the high dose metformin group and low dose metformin group.   One 
possible explanation for this discrepancy may lie in patient recall of pain.  The annual 
pain scores rely on the patient’s recall of pain. Previous studies have found that there can 
be inconsistencies in patient’s self-report of pain. Jamison, Sbrocco, and Parris (1989) 
reported that relying on the memory of chronic pain patients to accurately evaluate pain 
levels resulted in an overestimation of their pain intensity.  Although the Jamison et al. 
(1989) study population was not the same as our study population, their study did include 
back pain patients which is a similar population used in the Taylor et al. (2013) study of 
lumbar radiculopathic pain patients.  Recall that Taylor et al. (2013) reported a decrease 
in lumbar radiculopathic pain upon administration of metformin. 
This study utilized the SF-36 Brief Pain Score to rate pain. The SF-36 BPS is 
available in standard (4 weeks) and acute (1 week) recall versions. This study utilized the 
standard version and therefore relied on the patient’s recall of pain levels of the previous 
four weeks. Keller et al. (1997) compared both the standard and acute versions of the SF- 
36 and found that the acute version of the SF-36 was a more reliable form to utilize. Due 
to the use of the SF-36 standard version to measure pain in this study, it may not be 
reliable enough to truly measure the true pain level at each annual visit. 
Statistically significant change of pain score in year one and two on high dose 
(1,700 mg/day) metformin treatment compared to placebo and low dose (850 mg/day) 
metformin treatment along with significant changes seen between high dose metformin 
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patients and low dose metformin patients in year three provides support for the 
relationship that metformin has in decreasing pain.  Because this study utilized the less 
reliable standard version of the SF-36 BPS, a future study of yearly pain scores of 
metformin patients using the acute version of the SF-36 would be appropriate to 
determine if reported pain would indeed decrease.  Additionally, utilizing pain diaries, 
which require the subject to record pain levels on a daily basis, would also be another 
alternative means of ensuring greater accuracy in pain scores. This would eliminate the 
need for patients to rely on their recollection of pain levels over an extended period of 
time. 
Another factor that may play a role regarding the correlation of metformin to 
lower reported pain is the dose of metformin. Metformin can be prescribed at 850 mg 
once a day up to a maximum dose of 2,550 mg a day (Bristol-Myers Squibb, 2008; 
Appendix E). The maximum dose used in this study (1,700 mg/day) was below the 
recommended maintenance dose of metformin which is 2,000 mg a day (Bristol-Myers 
Squibb, 2008; Appendix E). 
Patients on the metformin arm of this study were initially given a dose of 850 mg 
of metformin to start.  If the medication was well tolerated, this dose was increased to 
850 mg twice a day for a total of 1,700 mg/day.  Although most patients (N = 425) did 
move on to the higher 1,700 mg/day dose, fifty-three patients remained on the lower 850 
mg/day dose. Twenty-eight patients were on mixed doses and were not used for this part 
of the analysis. 
There is the possibility that the 850 mg a day dose given to the low dose 
metformin group is too low of a dose to have a significant impact on pain scores.  If 850 
mg a day is too low, the low dose metformin group’s pain scores would more likely be 
93  
closer to that of the placebo group.  One animal study was found that tested the dose- 
dependent relationship of metformin and pain.   Melemedjian et al. (2011) treated mouse 
sensory neurons with 2 mM or 20 mM metformin for one hour. This study found a dose 
dependent increase in the phosphorylation of AMPK.  The higher dose of metformin 
caused increased phosphorylation of AMPK. 
In the initial part of the Melemedjian et al. (2011) study, rats were given 200 
mg/kg/day of metformin for seven days.  The rats weighed 250 to 300 grams for a dosage 
of 50 to 60 mg of metformin a day. This showed a resolution of induced-neuropathic 
allodynia.  If this dosage was adjusted for a human equivalent dose, it would equal 13,600 
mg of metformin/day for a 150-pound person, which is over the maximum dose of 1,700 
mg used in this study and over the maximum dose (2,550 mg) that can be prescribed. 
As noted, this study used a maximum dose of 1,700 mg of metformin per day and 
showed a significant difference in pain score when compared to a lower dose (850 
mg/day) of metformin in years one, two and three.  However, the high dose used in this 
study is lower than the recommended maintenance dose of 2,000 mg/day (Bristol-Myers 
Squibb, 2008).   Use of the maintenance dose of 2,000 mg/day up to the maximum dose 
of 2,550 mg/day is hypothesized to yield even better results on patient pain scores based 
on this study’s dose-dependent findings. 
An additional factor to consider is the use of extended release metformin. The 
starting dose of the extended release metformin is 500 to 1,000 mg per day with a max 
dose of 2,500 mg daily and a maintenance dose of 2,000 mg per day (Bristol-Myers 
Squibb, 2008). This is also higher than the dosage used for this study.  The extended 
release version slowly releases the active drug over the dosing period.  In addition, the 
extended release version of metformin has been shown to have fewer gastrointestinal side 
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effects than immediate release metformin (Blonde, Dailey, Jabbour, Reasner, & Mills, 
2004). 
Despite the lower-than-maintenance-dose of metformin used in this study along 
with the use of the immediate release metformin instead of the extended release version, 
this study still showed a significant decrease in pain with the 1,700 mg/day dose in years 
one, two and three.  This outcome is the most seminal result of this study.  No other 
study has found a correlation between dosage of metformin and less reported pain in a 
chronic pain human population. 
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5.3 Analysis of Secondary Aim 2 
 
Hypothesis #3A: Placebo patients will have more pain (lower SF-36 BPS) at year 
one, two, three and four compared to baseline. 
Hypothesis #3B: Low dose (850 mg/day) metformin patients will have no change 
in pain when comparing baseline, year one, year two, year three and year four 
pain scores. 
Hypothesis #3C: High dose (1,700 mg/day) metformin patients will have less 
pain (higher SF-36 BPS) when comparing year one, year two, year three and year 
four pain scores to baseline. 
The placebo group’s baseline, year one, two, three and four pain scores were 
compared using repeated measures ANOVA. The same was done for the low dose (850 
mg/day) metformin and high dose (1,700 mg/day) metformin groups. Because not all 
patients in this study followed up for all four years, only patients who had baseline, year 
one, two, three and four pain scores were used for this analysis. 
The placebo group (N = 336) pain scores differed between initial pain scores and 
year two pain scores (p = 0.012) and year one pain scores and year two pain scores (p = 
0.021) (Table 4.20). The pain increased from the initial score (M = 77.7) and year two 
score (M = 73.7) and from the year one pain score (M = 77.4) and year two pain score (M 
= 73.7).  This partially supports the hypothesis that the placebo group will have more 
pain (lower SF-36 BPS) annually.  Because these are pre-diabetic patients and one 
complication of pre-diabetes is chronic pain (mainly in the form of diabetic neuropathy), 
it is not surprising that without treatment for pain, patients should report greater pain over 
time.  However, even though a statistically significant difference in pain scores in year 
three and four, was not found, there was a meaningful clinical difference in pain scores 
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between baseline (M = 77.7) and year four (M = 74.7). The minimally important 
difference in the SP-36 BPS is three points (Ware et al., 2007). 
For the low dose (850 mg/day) metformin group, no statistical significance was 
seen among the baseline, year one, two, three and four pain scores (p = 0.195; Table 
4.23).  It was hypothesized that the low dose metformin group would have no change in 
pain scores throughout the duration of the study.   Because the placebo group showed an 
increase in pain when comparing baseline to year two and year one to year two, but the 
low dose metformin group showed no change in pain, it may indicate that the low dose 
metformin might have some pain relieving effects but not enough of an effect to improve 
pain scores. 
The high dose (1,700 mg/day) metformin group also showed no statistical 
significance among baseline, year one, two, three and four pain scores (p = 0.088; Table 
4.26). This result does not support hypothesis 3 of secondary aim 2.  It was hypothesized 
that the high dose metformin patients would report less pain annually (years 1 - 4).  As 
was explained with the low dose metformin group, the high dose metformin patients did 
not have an increase in pain (as seen in the placebo group) thus indicating that the high 
dose metformin may have some pain relieving effects. However, as stated in Section 5.2, 
the high dose used in this study (1,700 mg/day) is lower than the recommended 
maintenance dose of 2,000 mg/day and the maximum dose of 2,550 mg/day. Perhaps the 
low dose of 850 mg/day and high dose of 1,700 mg/day may provide some pain relief but 
the dosages may not be high enough to produce a statistically significant decrease in pain. 
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5.4 Significance of the Findings 
 
Overall, this study serves to evaluate the primary hypothesis that metformin use is 
correlated to less reported chronic pain in a pre-diabetic population. Even though the 
central hypothesis of the study was only proven in year two, the higher dose metformin 
patients did report less pain than placebo patients in years one and two and less pain than 
low dose metformin patients in years one, two and three.  This finding will make a 
significant contribution to the area of chronic pain in a diabetic population and possibly 
to other chronic pain populations. The finding that higher dose metformin use was 
partially correlated to less pain is novel in that no study to date has found this association 
in a human pre-diabetic population. 
Because of metformin’s low risk and high tolerability, it is imperative that this 
connection be further investigated as a possible pain relieving alternative to other 
medications not only for chronic pain associated with pre-diabetes but for other chronic 
pain conditions. 
This correlation has been seen in animal models (Mao-Ying et al., 2014; 
Melemedjian et al., 2011; Russe et al., 2013). However, there has only been one study to 
date (Taylor et al., 2013) which has considered the correlation between metformin and 
pain scores in a human population.  Like this study, Taylor et al. (2013) used 
retrospective analysis of pain scores and metformin use.  However, the population used in 
Taylor’s study was patients with lumbar radiculopathy.  Both lumbar radiculopathic pain 
and pre-diabetic pain (or diabetic neuropathy) are classified as chronic pain and have 
similar pain mechanisms. Therefore, it is not surprising that the current study also showed 
a correlation between metformin use and less pain. 
A novel finding of this study is the correlation between metformin dosage and 
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chronic pain.  The higher dose metformin patients (1,700 mg/day) reported much less 
pain than the patients on the lower dose (850 mg/day) of metformin in years one, two and 
three and the placebo patients in years one and two. No current study has addressed the 
possible correlation between metformin dosage and pain relief in a human population. 
The only study that analyzed the correlation of pain and metformin use in a human 
chronic pain population was Taylor et al. (2013) and the dosage was not mentioned or 
considered in their analysis. 
One animal study did investigate the correlation that metformin dose has on pain 
relief.   Melemedjian et al. (2011) found that there was a correlation between metformin 
dose and pain in a mouse model. However, the maximum dose used in Melemedjian’s 
study was equivalent to a dose of 13,600 mg/day for a 150 pound person.  This dosage is 
greater than the maximum dose of 2,550 mg/day that can be prescribed. Furthermore, 
Melemedjian et al. (2011) utilized mouse sensory nerves ex vivo for the dosage study. 
The results of that study relied on measured sensory nerve excitability as opposed to 
paw withdrawal thresholds which other studies have utilized to measure pain in animal 
models.  Ex vivo models do not take into account the interactions that other organ 
systems may play in the pain process. 
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5.5 Limitations 
 
A limitation of this study is that it was a retrospective analysis using data that was 
obtained from 1996 to 2008 in which the original aim of the study was not focused on 
pain. As such, the pain measurement used, the SF-36 BPS standard version, is not the 
most reliable source of measuring pain intensity.  The acute version of SF-36 is a more 
reliable way of measuring pain intensity (Keller et al., 1997). There is also an SF-36 
version 2 which is a more recent and improved version of the original SF-36.   
Additionally, the SF-36 utilizes self-report of pain, which is not an objective means of 
measuring pain.  Rosier, Iadarola, and Coghill (2002) found that the reproducibility of 
pain ratings from individual subjects was inconsistent despite attempts to control the 
experimental variables. A more objective way of measuring pain needs to be utilized in 
order to reduce variability in measurement. One potential method of objectively 
measuring pain is functional magnetic resonance imaging (fMRI). Wager et al. (2013) 
studied using fMRI to measure pain intensity during thermal stimuli. Perhaps this 
objective measurement would be the ideal way to truly measure pain intensity in chronic 
pain patients. 
Another limitation of this study is the dosage of metformin prescribed. There 
were only two doses, 850 mg/day and 1,700 mg/day, prescribed in this study.  The 
recommended maintenance dose of metformin is 2,000 mg a day with a maximum dose 
of 2,550 mg/day. This lower than maintenance dose may have limited the maximum 
potential that could potentially reduce pain. 
In addition, metformin also comes in an extended release form.  The extended 
release form of metformin also has a maintenance dose of 2,000 mg/day and has an added 
benefit of less GI side effects.  This form of metformin was not utilized in this study.  The 
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extended release form allows for a steady release of the drug over the course of the day, 
therefore potentially providing a decrease in the pain score variability that was seen in 
the year-by-year analysis.  The one caveat with using the extended release form of 
metformin is it has an increased monetary cost associated with its use compared to the 
immediate release form of metformin. 
Lastly, the sample size of the low dose metformin group must be addressed. 
 
While the overall sample size was adequate to conduct the study, sample size may have 
played a role in some of the analyses that were performed. Of all three groups, the low 
dose metformin group had the smallest sample size (N =53, 52, 51, 27 for baseline, year 
1, 2, 3 and 4 respectively).  The sample size was especially small in year four (N = 27) 
which may indicate the low post hoc power seen in year four (Table 5.1).  This may 
indicate a type II error in which the sample size of the low dose metformin group may be 
too small to reject the null hypothesis.  In addition to a possible type II error, there is 
also the possibility of inflation of type I error in doing multiple comparisons. To reduce 
type I error, we adjusted all analyses by performing post hoc tests (Tukey’s HSD, 
Bonferroni, Tamhane). 
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5.6 Further Research 
 
There are several prospective, double-blind, randomized future studies which 
would be recommended as a follow up to this study: 
1. Using a pre-diabetic population, evaluate pain scores for patients on 
placebo, 2,000 mg/day and 2,550 mg/day immediate release metformin and 500 mg/day, 
1,000 mg/day and 2,000 mg/day extended release metformin. Pain levels should be 
measured using the SF-36 v.2 BPS acute version. Pain scores should be measured at 
regular intervals, such as bi-annually or annually. 
2. Using patients with various chronic pain conditions such as low back pain, 
fibromyalgia, other types of neuropathy, evaluate pain scores using the SF-36 v.2 acute 
version of subjects on placebo, 2,000 mg/day and 2,550 mg/day immediate release 
metformin and 500 mg/day, 1,000 mg/day and 2,000 mg/day extended release metformin. 
Pain scores should be measured at regular intervals, such as bi-annually or annually. 
3. Using patients with diabetic neuropathy, evaluate pain scores of subjects 
on different pain medications (such as pregabalin, duloxetine, tapentadol) along with 
placebo,  2,000 mg/day and 2,550 mg/day immediate release metformin and 500 mg/day, 
1,000 mg/day and 2,000 mg/day extended release metformin.  Pain scores should be 
measured at regular intervals, such as bi-annually or annually. 
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5.7 Conclusion 
 
Higher dose metformin use is partly associated with less pain in a pre-diabetic 
population.   Patients on high dose (1,700 mg/day) metformin therapy had less pain than 
low dose (850 mg/day) metformin patients at year one, two and three (p = 0.005, 0.001, 
0.021 at years one, two and three respectively).  High dose metformin patients also had 
less pain than the placebo patients at year one and two (p = 0.047, 0.001 at years one and 
two respectively). 
The paramount finding of this study was that the dose of metformin was 
associated to the average end pain score.  The patients on the higher dose of metformin 
(1,700 mg/day) reported less pain than the patients on the lower dose of metformin (850 
mg/day) or placebo in years one, two and three.  This suggests that the dosage of 
metformin may also play a role in pain relief. 
This study serves to partially support the many animal studies which have shown 
the correlation between metformin use and pain reduction.  It is advantageous that future 
studies be done to further explore the potential for metformin to lower chronic pain.  In 
addition, using other chronic pain populations to substantiate this relationship, exploring 
the relationship of metformin dosage and extended release metformin effect on pain and 
comparing the pain relieving effect of metformin to other pain relieving medications is 
warranted. 
Future studies should address the dosage of metformin. The high dose (1,700 
mg/day) of metformin used in this study was lower than the recommended maintenance 
dose (2,000 mg/day) of metformin.  Since a correlation was found between metformin 
dosage and pain score, it would be worthwhile to increase the dose to the maintenance 
103  
dose or higher to see if the pain relieving effect continues or is amplified. 
The high tolerability and low side effects of metformin support the importance of 
exploring its pain-relieving potential. The numerous animal studies showing this 
potential needs to be further investigated in human chronic pain populations. This study 
plays an important role in further advancing our exploration of metformin’s ability of 
having an impact on relieving chronic pain. 
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